Skip to main content
UniHealth

Doctor search

Sunil S Dhawan, MD

Dermatology · Milpitas

NPI 1326018987

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
36
10 carriers
Office
1

Offices

1 location · East Bay Dermatology Medical Group Inc. · 8 clinicians in this group

Looking this up.

Hospitals listed: Washington Hospital. That is not proof they admit you there this week.

Plans that list them

36 plans · 10 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dhawan’s office at (408) 957-7676 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

36 of 36 plans

Plans whose provider directory lists this clinician
Advantage Care (HMO)Align Senior CareListedOct 1, 2026
Premier Care (HMO I-SNP)Align Senior CareListedOct 1, 2026
Senior Care (HMO I-SNP)Align Senior CareListedOct 1, 2026
Alignment Health Advantage PPO (PPO)Alignment Health PlanListedOct 3, 2026
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
Anthem Medicare Advantage (HMO-POS)Anthem Blue CrossListedOct 3, 2026
Anthem Prime (HMO-POS)Anthem Blue Cross Partnership PlanListedOct 3, 2026
Astiva Health C-SNP WOW - NorCal (HMO C-SNP)Astiva HealthListedSep 27, 2026
Astiva Health Premier Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Astiva Health Savings Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Blue Shield Inspire (HMO)Blue Shield of CaliforniaListedAug 26, 2026
Central Health Classic Care Plan III (HMO)Central Health Medicare PlanListedAug 15, 2026
Central Health Dual Access Plan (HMO D-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Embrace Care Plan (HMO C-SNP)Central Health Medicare PlanListed, may be out of dateSep 15, 2025
Central Health Embrace Choice Plan (HMO C-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Valor Care Plan (HMO)Central Health Medicare PlanListedAug 15, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G53340 · Current

Licensed to practise in California · since 1984 · expires 2028-04-30 · University of Southern California Keck School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend it
    Overall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Washington Hospital

Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Washington Hospital
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.188BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.164BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.88 (0 to 1.88) · 1,112 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.92 (0.59 to 1.24)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths192.95 (139.54 to 246.36) · 48 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2 · 27 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.4 · 164 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.1 · 199 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8.9 · 463 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths15.6 · 661 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.3 · 174 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.7 · 2,550 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.15 (0 to 0.35) · 6,970 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.4) · 7,108 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.82 (1.73 to 5.91) · 1,370 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.52 (0 to 3.17) · 589 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.75 (0.25 to 3.25) · 1,315 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths13.19 (5.83 to 20.56) · 600 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.91 (1.04 to 8.78) · 550 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.66 (0.17 to 3.14) · 198 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.14 (0 to 0.78) · 6,079 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.7 · 114 casesNoneApr 2023 – Mar 2025
MRSA BacteremiaInfections0No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.367No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.8 · 186 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.9 · 480 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits33.9 · 186 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits26.5 · 553 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits36.8 · 648 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.5 · 590 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.7 (3.2 to 6.9) · 169 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11.4 (8.5 to 14.9) · 169 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.4 · 130 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11.1 · 41 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.3 · 202 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.7 (10.2 to 18.5) · 78 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.1) · 974 casesNo differentJan 2024 – Dec 2024

What patients said (812 patients answered, 19% of those asked)

Patient survey stars by topic at Washington Hospital
Cleanliness4
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information3
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Washington Hospital
Room was "always" clean76%
Nurses "always" communicated well77%
Doctors "always" communicated well77%
Staff "always" explained56%
Yes, staff "did" give patients this information84%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand70%
Doctors "always" listened carefully76%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)71%
Staff "always" explained new medications70%
Nurses "always" explained things so they could understand72%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night46%
"YES", patients would definitely recommend the hospital71%
Staff "always" explained possible side effects42%
Yes, staff "did" give patients information about possible symptoms84%

Original Medicare doctor bills

$430,997

Medicare paid this office $430,997 for 1,258 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Short return visit (20+ min)794$98,675$75
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm22$42,247$158
Return visit (30+ min)177$30,589$109
Destruction of skin growth, 1-14 growths205$30,474$108
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application22$27,526$129
See all 31 services
Every Original Medicare service billed
Short return visit (20+ min)794$98,675$75
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm22$42,247$158
Return visit (30+ min)177$30,589$109
Destruction of skin growth, 1-14 growths205$30,474$108
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application22$27,526$129
Destruction of precancer skin growth, 1 growth298$22,542$54
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg68$18,845None
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm16$18,382$170
Short return visit252$15,756$48
New patient visit (30+ min)186$15,756$85
Application of light by qualified health care professional to destroy precancer skin growth60$13,783$222
Punch biopsy, first skin growth82$10,081$115
Destruction of precancer skin growth, 2-14 growths223$9,189$6
Destruction of precancer skin growth, 15 or more growths31$6,354$163
Biopsy of related skin growth, first growth58$5,767$95
Injection into skin growth, 1-7 growths55$4,970$51
Destruction of skin growth, 15 or more growths22$3,990$125
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm12$3,771$290
New patient visit (45+ min)32$3,673$115
Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm26$3,329$115
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less13$2,979$229
Simple or single drainage of skin abscess24$2,978$106
New patient visit (15+ min)55$2,741$50
Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm23$2,572$107
Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less19$2,091$105
Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm14$1,694$113
Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm12$1,617$124
Injection into skin growth, more than 7 growths13$1,268$55
Biopsy of related skin growth, each additional growth14$725$52
Injection of drug or substance under skin or into muscle13$255$14
Injection, triamcinolone acetonide, not otherwise specified, 10 mg65$126None

Procedures Medicare counted

Procedure volume Medicare published
Melanoma (skin cancer) excision22More than 76% of doctors who do this
Removal of nail tissue1-10None
Removal of skin lesions1010More than 93% of doctors who do this
Removal of tissue1-10None
Removal or shaving of skin growth150More than 88% of doctors who do this
Skin biopsy132More than 79% of doctors who do this

Who their Medicare patients are

1,258 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 51% · Also on Medicaid 34% · Health risk score 1.13. Above the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 75% · Diabetes 38% · Coronary heart disease 26% · Chronic kidney disease 23% · Atrial fibrillation 15% · Heart failure 13% · Cancer 12% · Depression 12% · COPD 11% · Stroke 7% · Dementia 6%.

The office billed $1,260,826, Medicare allowed $598,363 and paid $430,997; for 20,106 services of 59 kinds; $18,971 of it was for drugs given in the office and $412,027 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20241,25820,106751.13$1,260,826$430,997
20231,17114,903751.11$857,756$419,496
20221,20717,253751.12$1,075,021$543,981
20211,09416,925741.11$886,329$515,967
20201,27622,024751.16$836,133$533,218
20191,66421,419751.22$837,529$536,237
20181,67017,567751.19$766,879$516,635
20171,78611,527741.22$800,630$536,780
20161,1146,727741.25$478,589$297,602
20151,1066,689741.25$522,502$333,837
20148995,091741.13$501,251$300,722
20138234,920741.31$462,422$296,004

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 30 services

Original Medicare services billed in 2023
Short return visit (20+ min)719$93,729$76
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm16$38,753$164
Treatment of inflammatory skin disease using laser, more than 500.0 sq cm12$35,758$242
Destruction of skin growth, 1-14 growths187$28,659$107
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm15$26,124$178
Return visit (30+ min)164$25,856$110
Destruction of precancer skin growth, 1 growth261$22,141$57
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application23$21,154$130
New patient visit (30+ min)166$14,161$85
Short return visit206$12,039$47
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg45$11,940None
Destruction of precancer skin growth, 2-14 growths209$10,307$7
Application of light by qualified health care professional to destroy precancer skin growth42$9,578$218
Punch biopsy, first skin growth62$8,092$123
Destruction of precancer skin growth, 15 or more growths34$7,024$167
Biopsy of related skin growth, first growth63$6,913$95
Injection into skin growth, 1-7 growths50$4,323$45
New patient visit (45+ min)31$4,153$134
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm13$3,843$296
Destruction of skin growth, 15 or more growths20$3,291$113
Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm18$2,266$119
Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm17$1,921$107
New patient visit (15+ min)34$1,811$53
Pathology examination of tissue using a microscope, intermediate complexity23$1,774$54
Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm11$1,358$123
Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less12$1,236$103
Simple or single drainage of skin abscess11$1,222$111
Biopsy of related skin growth, each additional growth11$793$53
Pathology examination of tissue using a microscope, moderately low complexity13$623$39
Injection, triamcinolone acetonide, not otherwise specified, 10 mg58$117None

2022: 28 services

Original Medicare services billed in 2022
Short return visit (20+ min)767$96,462$78
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm17$39,179$181
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm21$35,434$163
Destruction of skin growth, 1-14 growths222$33,844$109
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks43$24,498$521
High dose rate electronic brachytherapy, external12$22,950$134
Destruction of precancer skin growth, 1 growth285$22,774$56
Short return visit310$20,125$48
New patient visit (30+ min)198$17,110$86
Return visit (30+ min)115$16,497$109
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks23$15,521$419
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application21$14,318$128
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg47$13,648None
Application of light by qualified health care professional to destroy precancer skin growth43$11,383$232
Destruction of precancer skin growth, 2-14 growths237$11,001$7
Punch biopsy, first skin growth68$9,511$130
Biopsy of related skin growth, first growth89$9,125$97
Destruction of precancer skin growth, 15 or more growths35$7,395$168
Injection into skin growth, 1-7 growths62$5,358$47
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm16$5,210$306
Destruction of skin growth, 15 or more growths28$4,386$107
New patient visit (15+ min)50$3,012$60
Pathology examination of tissue using a microscope, intermediate complexity28$2,741$69
New patient visit (45+ min)15$2,152$143
Simple or single drainage of skin abscess17$2,141$113
Injection into skin growth, more than 7 growths13$1,063$56
Biopsy of related skin growth, each additional growth11$691$53
Injection, triamcinolone acetonide, not otherwise specified, 10 mg76$161None

2021: 31 services

Original Medicare services billed in 2021
Short return visit (20+ min)676$86,609$76
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks69$38,220$531
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks44$34,459$415
Destruction of skin growth, 1-14 growths188$30,546$111
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm14$28,534$188
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application23$27,577$125
Short return visit342$24,354$45
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm17$24,160$162
New patient visit (30+ min)200$19,766$99
Destruction of precancer skin growth, 1 growth239$18,773$54
Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less17$17,773$987
Biopsy of related skin growth, first growth153$17,643$100
Return visit (30+ min)91$13,979$103
Application of light by qualified health care professional to destroy precancer skin growth52$13,651$235
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg53$13,577None
Punch biopsy, first skin growth71$10,279$133
Pathology examination of tissue using a microscope, intermediate complexity93$10,105$72
Destruction of precancer skin growth, 2-14 growths195$8,793$6
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm20$7,384$308
Injection into skin growth, 1-7 growths60$6,313$51
Destruction of precancer skin growth, 15 or more growths31$6,235$160
Destruction of skin growth, 15 or more growths21$4,343$132
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less14$4,338$289
New patient visit (15+ min)55$3,564$65
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less11$2,945$268
Simple or single drainage of skin abscess16$2,016$126
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm12$1,399$117
Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less12$1,181$98
Biopsy of related skin growth, each additional growth13$718$55
Pathology examination of tissue using a microscope, moderately low complexity12$617$44
Injection, triamcinolone acetonide, not otherwise specified, 10 mg64$201None

2020: 29 services

Original Medicare services billed in 2020
Short return visit (20+ min)558$54,359$65
Short return visit670$49,609$40
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm22$40,993$167
Destruction of skin growth, 1-14 growths246$37,213$108
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm19$30,444$186
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application25$28,633$123
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks28$28,140$408
Destruction of precancer skin growth, 1 growth347$26,446$53
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks37$20,715$482
Biopsy of related skin growth, first growth174$19,551$95
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg65$16,383None
Pathology examination of tissue using a microscope, intermediate complexity155$16,307$69
Application of light by qualified health care professional to destroy precancer skin growth61$16,035$226
Treatment of inflammatory skin disease using laser, more than 500.0 sq cm12$15,783$247
Destruction of precancer skin growth, 2-14 growths286$12,603$6
Destruction of precancer skin growth, 15 or more growths54$9,691$154
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm30$9,201$297
Punch biopsy, first skin growth64$8,547$124
New patient visit (15+ min)157$8,470$54
New patient visit (30+ min)91$8,279$91
Injection into skin growth, 1-7 growths80$6,333$45
Return visit (30+ min)51$6,210$94
Destruction of skin growth, 15 or more growths23$4,944$121
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less17$4,943$275
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less17$4,489$249
Simple or single drainage of skin abscess25$2,942$113
Biopsy of related skin growth, each additional growth17$1,036$55
Pathology examination of tissue using a microscope, moderately low complexity11$471$43
Injection, triamcinolone acetonide, not otherwise specified, 10 mg87$193None

2019: 33 services

Original Medicare services billed in 2019
Short return visit1,009$74,263$40
Short return visit (20+ min)703$69,347$66
Destruction of skin growth, 1-14 growths300$51,090$108
Destruction of precancer skin growth, 1 growth471$39,172$58
Treatment of inflammatory skin disease using laser, more than 500.0 sq cm11$27,977$233
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm11$26,753$180
Biopsy of related skin growth, first growth216$23,254$93
Pathology examination of tissue using a microscope, intermediate complexity206$20,863$66
New patient visit (15+ min)316$20,767$66
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm20$19,129$156
Destruction of precancer skin growth, 2-14 growths394$15,618$5
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application21$15,348$94
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm42$14,035$292
Punch biopsy, first skin growth104$13,749$125
Destruction of precancer skin growth, 15 or more growths68$13,203$140
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg67$12,664None
New patient visit (30+ min)100$9,930$99
Injection into skin growth, 1-7 growths79$6,752$48
Application of light to destroy precancer skin growth45$5,901$126
Destruction of skin growth, 15 or more growths27$5,109$128
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm16$4,278$267
Return visit (30+ min)35$4,127$98
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm24$3,668$126
Application of light with debridement to destroy precancer skin growth11$3,477$267
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less12$2,798$233
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less11$2,573$234
Application of light by qualified health care professional to destroy precancer skin growth12$2,485$207
Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm16$2,171$136
Simple or single drainage of skin abscess16$1,752$97
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm11$1,747$146
Application of ultraviolet light to skin11$1,583$22
Biopsy of related skin growth, each additional growth26$1,347$52
Injection, triamcinolone acetonide, not otherwise specified, 10 mg85$233None

2018: 32 services

Original Medicare services billed in 2018
Short return visit1,018$68,823$37
Short return visit (20+ min)672$58,855$59
Destruction of skin growth, 1-14 growths292$46,882$101
Destruction of precancer skin growth, 1 growth485$40,386$53
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm15$37,656$169
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm25$32,895$144
Biopsy of single growth of skin and/or tissue302$32,011$94
Treatment of inflammatory skin disease using laser, more than 500.0 sq cm14$30,646$229
Pathology examination of tissue using a microscope, intermediate complexity216$19,582$64
New patient visit (15+ min)314$18,219$58
Destruction of precancer skin growth, 2-14 growths428$17,816$5
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm39$12,100$288
Destruction of precancer skin growth, 15 or more growths74$12,052$128
New patient visit (30+ min)116$10,519$91
Injection into skin growth, 1-7 growths90$8,194$47
Therapy procedure using ultraviolet radiation with tar or petroleum jelly application18$8,044$72
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg42$7,483None
Application of ultraviolet light to skin22$4,165$18
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm14$3,726$266
Destruction of skin growth, 15 or more growths18$3,536$118
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less16$3,478$217
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less14$3,262$217
Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm13$3,124$240
Application of light to destroy precancer skin growth26$3,058$105
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm20$2,571$112
Application of light by qualified health care professional to destroy precancer skin growth13$2,377$183
Simple or single drainage of skin abscess21$2,216$106
Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm14$1,962$140
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm12$1,858$143
Biopsy of each additional growth of skin and/or tissue22$674$29
Pathology examination of tissue using a microscope, moderately low complexity12$482$40
Injection, triamcinolone acetonide, not otherwise specified, 10 mg98$326None

2017: 28 services

Original Medicare services billed in 2017
Short return visit (20+ min)741$61,638$58
Short return visit995$60,083$35
Treatment of inflammatory skin disease using laser, more than 500.0 sq cm19$44,748$223
Destruction of skin growth, 1-14 growths303$44,748$99
Destruction of precancer skin growth, 1 growth543$43,094$52
Biopsy of single growth of skin and/or tissue354$37,783$90
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm22$36,953$143
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm19$25,741$160
Pathology examination of tissue using a microscope, intermediate complexity252$23,553$63
New patient visit (15+ min)345$19,072$55
Destruction of precancer skin growth, 2-14 growths476$18,711$5
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)51$15,571None
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm47$13,715$269
Destruction of precancer skin growth, 15 or more growths81$13,610$131
New patient visit (30+ min)145$12,093$83
Application of ultraviolet light to skin26$8,382$20
Application of light to destroy precancer skin growth51$6,856$122
Injection into skin growth, 1-7 growths80$6,809$44
Destruction of skin growth, 15 or more growths14$3,591$109
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm30$3,555$111
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm12$3,222$269
Simple or single drainage of skin abscess18$2,003$100
Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm12$1,617$135
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm11$1,073$98
Biopsy of each additional growth of skin and/or tissue34$1,003$28
Pathology examination of tissue using a microscope, moderately low complexity16$635$37
Injection of drug or substance under skin or into muscle15$491$25
Injection, triamcinolone acetonide, not otherwise specified, 10 mg94$339None

2016: 21 services

Original Medicare services billed in 2016
Short return visit673$41,216$36
Short return visit (20+ min)388$31,837$59
Destruction of precancer skin growth, 1 growth326$26,280$53
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm13$24,601$146
Destruction of skin growth, 1-14 growths160$21,918$100
Biopsy of single growth of skin and/or tissue164$16,668$92
Pathology examination of tissue using a microscope, intermediate complexity124$12,070$68
New patient visit (15+ min)205$11,959$58
Destruction of precancer skin growth, 2-14 growths281$11,268$5
Application of ultraviolet light to skin17$7,971$20
New patient visit (30+ min)91$7,473$82
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm18$5,990$272
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)20$5,552None
Injection into skin growth, 1-7 growths69$5,240$46
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less14$3,332$238
Destruction of skin growth, 15 or more growths15$3,267$113
Application of light to destroy precancer skin growth20$2,803$117
Destruction of precancer skin growth, 15 or more growths20$2,709$129
Simple or single drainage of skin abscess23$2,476$103
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less11$2,417$220
Injection, triamcinolone acetonide, not otherwise specified, 10 mg74$158None

2015: 22 services

Original Medicare services billed in 2015
Short return visit680$50,119$39
Treatment of inflammatory skin disease using laser, more than 500.0 sq cm11$34,035$227
Destruction of skin growth, 1-14 growths202$30,914$104
Destruction of precancer skin growth, 1 growth306$26,752$57
Short return visit (20+ min)302$26,106$63
Biopsy of single growth of skin and/or tissue166$17,573$95
New patient visit (30+ min)149$13,475$90
New patient visit (15+ min)199$12,705$64
Pathology examination of tissue using a microscope, intermediate complexity124$12,405$69
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm11$11,951$166
Destruction of precancer skin growth, 2-14 growths258$10,895$5
Application of ultraviolet light to skin20$8,990$20
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm17$5,419$285
Injection into skin growth, 1-7 growths66$5,256$48
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)21$4,378None
Destruction of precancer skin growth, 15 or more growths24$3,860$138
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less16$3,709$218
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less15$3,551$222
Application of light to destroy precancer skin growth20$2,735$124
Destruction of skin growth, 15 or more growths17$2,637$120
Simple or single drainage of skin abscess13$1,249$96
Injection, triamcinolone acetonide, not otherwise specified, 10 mg69$147None

2014: 22 services

Original Medicare services billed in 2014
Treatment of inflammatory skin disease using laser, more than 500.0 sq cm17$72,095$225
Short return visit596$41,532$38
Destruction of precancer skin growth, 1 growth239$23,577$66
Destruction of skin growth, 1-14 growths150$21,775$101
Short return visit (20+ min)189$16,932$62
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm14$15,673$160
Biopsy of single growth of skin and/or tissue139$14,006$93
Destruction of precancer skin growth, 2-14 growths204$12,817$9
New patient visit (15+ min)145$9,185$63
Pathology examination of tissue using a microscope, intermediate complexity97$8,938$66
New patient visit (30+ min)79$7,375$93
Injection into skin growth, 1-7 growths74$5,761$48
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm17$5,026$279
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)25$4,417None
Application of ultraviolet light to skin19$4,408$20
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less15$3,115$208
Application of light to destroy precancer skin growth25$2,857$114
Destruction of skin growth, 15 or more growths11$2,246$125
Destruction of precancer skin growth, 15 or more growths14$1,880$134
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm12$1,472$123
Pathology examination of tissue using a microscope, moderately low complexity15$674$42
Injection, triamcinolone acetonide, not otherwise specified, 10 mg82$171None

2013: 24 services

Original Medicare services billed in 2013
Treatment of inflammatory skin disease using laser, more than 500.0 sq cm11$50,389$234
Short return visit577$47,856$40
Destruction of precancer skin growth, 1 growth196$23,721$76
Treatment of inflammatory skin disease using laser, less than 250.0 sq cm12$20,067$154
Destruction of skin growth, 1-14 growths124$19,144$109
Treatment of inflammatory skin disease using laser, 250.0-500.0 sq cm13$19,104$169
Short return visit (20+ min)191$18,267$64
Biopsy of single growth of skin and/or tissue120$13,090$100
New patient visit (15+ min)156$10,386$67
Pathology examination of tissue using a microscope, intermediate complexity78$7,888$67
Destruction of precancer skin growth, 2-14 growths162$7,871$6
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm22$6,448$293
Injection into skin growth, 1-7 growths63$5,318$50
Application of ultraviolet light to skin17$4,852$22
New patient visit (30+ min)50$4,688$94
Destruction of skin growth, 15 or more growths11$3,966$132
Application of light to destroy precancer skin growth17$2,705$142
Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less11$2,483$226
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)17$2,439None
Simple or single drainage of skin abscess15$1,768$111
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm14$1,650$118
Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes15$1,027$38
Pathology examination of tissue using a microscope, moderately low complexity13$609$43
Injection, triamcinolone acetonide, not otherwise specified, 10 mg67$153None

Medicaid work

$195,567 in 2024

Medicaid paid $195,567 for 4,505 billed services this clinician did in 2024, up to 167 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Short return visit (20+ min)1,736$69,054
Return visit (30+ min)903$54,439
New patient visit (30+ min)562$26,939
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions290$15,862
New patient visit (45+ min)83$6,523
Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B102$5,208
Injection, intralesional; up to and including 7 lesions177$5,147
Short return visit145$4,638
OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES66$2,703
Excimer laser treatment for psoriasis; total area less than 250 sq cm30$2,177
Punch biopsy of skin (including simple closure, when performed); single lesion12$1,066
Injection, triamcinolone acetonide, not otherwise specified, 10 mg359$824
Medicaid work by year
20244,50514167$195,567
20234,82313172$247,881
20223,37811177$191,376
20213,1429134$212,362
20202,3486110$154,453
20192,9518157$210,977
20182,5339114$181,751
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Short return visit (20+ min)1,370$57,994
Return visit (30+ min)901$53,727
Excimer laser treatment for psoriasis; total area less than 250 sq cm406$45,703
New patient visit (30+ min)605$35,736
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions248$16,692
Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B162$11,237
New patient visit (45+ min)128$10,908
Injection, intralesional; up to and including 7 lesions296$6,678
Short return visit169$5,067
OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES63$1,597
Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion26$1,371
Injection, triamcinolone acetonide, not otherwise specified, 10 mg419$827

2022

Largest Medicaid services in 2022
Short return visit (20+ min)1,364$84,100
New patient visit (30+ min)586$34,368
Return visit (30+ min)439$31,022
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions193$14,756
Injection, intralesional; up to and including 7 lesions244$9,129
Short return visit149$6,570
New patient visit (45+ min)61$5,492
Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B27$2,967
Punch biopsy of skin (including simple closure, when performed); single lesion12$1,126
Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion17$1,046
Injection, triamcinolone acetonide, not otherwise specified, 10 mg286$800

2021

Largest Medicaid services in 2021
Short return visit (20+ min)1,328$99,019
New patient visit (30+ min)711$50,165
Return visit (30+ min)392$35,741
Injection, intralesional; up to and including 7 lesions231$9,306
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions89$8,805
Short return visit90$5,271
Punch biopsy of skin (including simple closure, when performed); single lesion25$1,795
Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion16$1,420
Injection, triamcinolone acetonide, not otherwise specified, 10 mg260$840

2020

Largest Medicaid services in 2020
Short return visit (20+ min)789$55,014
New patient visit (30+ min)461$49,467
Short return visit712$34,269
Injection, intralesional; up to and including 7 lesions136$8,217
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions67$6,659
Injection, triamcinolone acetonide, not otherwise specified, 10 mg183$828

2019

Largest Medicaid services in 2019
Short return visit1,196$57,825
New patient visit (30+ min)494$46,569
Short return visit (20+ min)567$38,770
Excimer laser treatment for psoriasis; over 500 sq cm106$25,124
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions164$20,328
Injection, intralesional; up to and including 7 lesions178$11,441
Excimer laser treatment for psoriasis; 250 sq cm to 500 sq cm40$10,022
Injection, triamcinolone acetonide, not otherwise specified, 10 mg206$898

2018

Largest Medicaid services in 2018
Short return visit1,099$56,232
New patient visit (30+ min)372$44,675
Short return visit (20+ min)386$28,278
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions202$27,866
Injection, intralesional; up to and including 7 lesions215$15,613
Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B40$3,997
Service25$3,168
Injection, triamcinolone acetonide, not otherwise specified, 10 mg182$987
OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES12$933

Drugs they prescribed that Part D paid

$594,121

Pharmacies billed $594,121 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 2,222) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

2,088 generic and 134 brand-name prescriptions · $594,121 in drug cost · 83 antibiotic prescriptions to 39 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Enbrel Sureclick17$150,823$8,872
Otezla13$53,421$4,109
Betamethasone Dipropionate183$10,822$59
Calcipotriene60$8,382$140
Tacrolimus60$8,084$135
See all 35 drugs
Every Part D drug this clinician prescribed
Enbrel Sureclick17$150,823$8,872
Otezla13$53,421$4,109
Betamethasone Dipropionate183$10,822$59
Calcipotriene60$8,382$140
Tacrolimus60$8,084$135
Fluocinonide175$7,287$42
Ketoconazole192$4,309$22
Fluorouracil47$3,315$71
Doxycycline Hyclate39$2,927$75
Clindamycin Phosphate84$2,703$32
Desonide50$2,366$47
Mometasone Furoate107$2,112$20
Triamcinolone Acetonide185$2,021$11
Azelaic Acid24$2,001$83
Metronidazole29$1,604$55
Tretinoin29$1,486$51
Hydrocortisone251$1,452$6
Clobetasol Propionate17$1,308$77
Adapalene12$1,114$93
Econazole Nitrate36$1,025$28
Valacyclovir23$987$43
Betamethasone Diprop Augmented18$986$55
Selenium Sulfide58$830$14
Ciclopirox34$812$24
Hydroxyzine111$788$7
Fluticasone Propionate18$714$40
Mupirocin68$483$7
Doxycycline Monohydrate21$374$18
Spironolactone17$351$21
Imiquimod17$279$16
Minoxidil30$181$6
Terbinafine13$122$9
Cephalexin11$63$6
Prednisone11$36$3
Hydroxychloroquine Sulfate12$12$1

Year by year

Part D prescribing by year
20242,2226410% (0)6%$594,121
20232,139660NoneNone$585,516
20222,069660None10%$910,814
20211,980596None12%$606,478
20202,077587None11%$462,416
20192,106670None11%$377,572
20181,9796420% (0)None$414,729
20172,250742NoneNone$352,437
20162,319697NoneNone$305,931
20152,248624NoneNone$318,192
20142,093593NoneNone$246,269
20132,2515920% (0)None$192,990

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 34 drugs

Part D drugs prescribed in 2023
Enbrel Sureclick11$116,289$10,572
Otezla17$79,307$4,665
Betamethasone Dipropionate177$14,067$79
Tacrolimus52$13,262$255
Calcipotriene53$12,178$230
Fluocinonide219$11,951$55
Calcipotriene-Betamethasone13$7,658$589
Clindamycin Phosphate118$6,165$52
Ketoconazole159$4,583$29
Fluorouracil33$4,405$133
Metronidazole33$3,889$118
Tretinoin44$3,377$77
Clobetasol Propionate27$2,862$106
Mometasone Furoate113$2,707$24
Triamcinolone Acetonide182$2,504$14
Desonide28$2,334$83
Econazole Nitrate34$1,666$49
Fluocinolone Acetonide24$1,603$67
Hydrocortisone220$1,575$7
Doxycycline Hyclate28$1,490$53
Valacyclovir29$1,171$40
Selenium Sulfide60$1,091$18
Doxycycline Monohydrate24$982$41
Hydroxyzine71$959$14
Ciclopirox17$867$51
Betamethasone Diprop Augmented19$789$42
Clotrimazole22$689$31
Mupirocin61$614$10
Fluticasone Propionate16$413$26
Imiquimod17$284$17
Minocycline12$245$20
Gabapentin12$238$20
Minoxidil19$172$9
Prednisone13$41$3

2022: 34 drugs

Part D drugs prescribed in 2022
Enbrel Sureclick32$274,589$8,581
Otezla37$162,325$4,387
Enbrel Mini15$103,722$6,915
Cosentyx Pen (2 Pens)11$71,724$6,520
Dupixent12$43,702$3,642
Fluocinonide282$20,216$72
Betamethasone Dipropionate158$14,584$92
Tacrolimus46$12,443$270
Calcipotriene56$10,509$188
Ketoconazole166$4,853$29
Clindamycin Phosphate66$4,033$61
Fluorouracil34$3,477$102
Clobetasol Propionate40$2,784$70
Desonide30$2,583$86
Tretinoin45$2,547$57
Triamcinolone Acetonide165$2,538$15
Metronidazole31$2,425$78
Econazole Nitrate39$1,826$47
Mometasone Furoate54$1,807$33
Hydroxyzine104$1,229$12
Doxycycline Hyclate31$1,158$37
Fluocinolone Acetonide16$1,136$71
Hydrocortisone135$1,090$8
Betamethasone Diprop Augmented22$1,005$46
Ciclopirox25$994$40
Mupirocin80$852$11
Selenium Sulfide45$571$13
Fluticasone Propionate14$496$35
Clotrimazole19$431$23
Doxycycline Monohydrate14$414$30
Valacyclovir13$414$32
Cephalexin19$165$9
Terbinafine15$148$10
Prednisone11$71$6

2021: 33 drugs

Part D drugs prescribed in 2021
Enbrel Sureclick19$157,047$8,266
Otezla20$81,676$4,084
Cosentyx Pen (2 Pens)13$76,248$5,865
Dupixent14$47,367$3,383
Fluocinonide291$20,664$71
Enstilar12$15,156$1,263
Calcipotriene-Betamethasone Dp12$12,484$1,040
Betamethasone Dipropionate155$11,106$72
Tacrolimus43$8,642$201
Pimecrolimus12$7,390$616
Calcipotriene38$6,472$170
Ketoconazole132$4,174$32
Tretinoin49$3,422$70
Fluorouracil32$3,415$107
Metronidazole38$3,340$88
Clindamycin Phosphate57$3,177$56
Clobetasol Propionate57$3,058$54
Desonide32$2,786$87
Triamcinolone Acetonide174$2,727$16
Betamethasone Diprop Augmented24$1,845$77
Doxycycline Hyclate40$1,282$32
Mometasone Furoate38$1,073$28
Hydrocortisone132$936$7
Ciclopirox30$881$29
Mupirocin72$861$12
Selenium Sulfide75$842$11
Econazole Nitrate22$784$36
Hydroxyzine72$674$9
Clotrimazole24$601$25
Doxycycline Monohydrate17$398$23
Cephalexin24$147$6
Gabapentin11$125$11
Prednisone12$108$9

2020: 32 drugs

Part D drugs prescribed in 2020
Enbrel Sureclick17$102,309$6,018
Dupixent19$61,207$3,221
Otezla11$41,062$3,733
Fluocinonide344$23,204$67
Calcipotriene59$11,754$199
Betamethasone Dipropionate119$8,266$69
Pimecrolimus14$7,612$544
Ketoconazole176$6,278$36
Fluorouracil39$6,095$156
Tacrolimus20$5,039$252
Clindamycin Phosphate50$3,488$70
Tretinoin58$3,170$55
Triamcinolone Acetonide195$3,017$15
Metronidazole33$2,928$89
Clobetasol Propionate54$2,847$53
Desonide30$2,253$75
Betamethasone Diprop Augmented26$2,237$86
Doxycycline Hyclate56$1,838$33
Fluocinolone Acetonide20$1,509$75
Econazole Nitrate40$1,452$36
Ciclopirox37$1,050$28
Hydrocortisone134$930$7
Selenium Sulfide75$896$12
Clotrimazole46$846$18
Hydroxyzine65$750$12
Fluticasone Propionate17$658$39
Mupirocin72$599$8
Doxycycline Monohydrate14$481$34
Minocycline12$457$38
Mometasone Furoate20$426$21
Valacyclovir12$356$30
Cephalexin24$86$4

2019: 32 drugs

Part D drugs prescribed in 2019
Enbrel Sureclick15$75,140$5,009
Otezla17$59,177$3,481
Fluocinonide370$22,736$61
Calcipotriene51$11,869$233
Tacrolimus18$7,051$392
Betamethasone Dipropionate105$7,004$67
Clindamycin Phosphate84$6,480$77
Ketoconazole170$5,751$34
Fluorouracil39$5,476$140
Clobetasol Propionate53$4,918$93
Metronidazole39$3,801$97
Econazole Nitrate55$3,619$66
Desonide33$2,956$90
Tretinoin35$2,939$84
Triamcinolone Acetonide252$2,912$12
Imiquimod24$2,253$94
Betamethasone Diprop Augmented26$1,537$59
Fluocinolone Acetonide15$1,417$94
Ciclopirox37$1,244$34
Doxycycline Hyclate22$1,221$56
Hydrocortisone153$1,107$7
Doxycycline Monohydrate27$1,062$39
Selenium Sulfide78$916$12
Clotrimazole42$850$20
Mupirocin63$668$11
Fluticasone Propionate18$625$35
Hydroxyzine50$545$11
Valacyclovir11$413$38
Mometasone Furoate20$409$20
Minocycline15$308$21
Cephalexin15$229$15
Gabapentin11$73$7

2018: 30 drugs

Part D drugs prescribed in 2018
Enbrel Sureclick18$103,759$5,764
Otezla29$96,483$3,327
Fluocinonide374$27,336$73
Calcipotriene39$15,917$408
Clobetasol Propionate89$11,600$130
Econazole Nitrate60$6,819$114
Fluorouracil46$6,543$142
Desonide46$6,500$141
Clindamycin Phosphate73$6,443$88
Ketoconazole133$5,382$40
Betamethasone Dipropionate74$5,185$70
Tacrolimus15$4,219$281
Triamcinolone Acetonide203$2,969$15
Tretinoin21$2,636$126
Metronidazole24$2,473$103
Hydrocortisone204$1,642$8
Betamethasone Diprop Augmented15$1,518$101
Fluocinolone Acetonide16$1,420$89
Doxycycline Hyclate16$1,042$65
Clotrimazole34$964$28
Selenium Sulfide69$691$10
Hydroxyzine40$670$17
Imiquimod12$649$54
Ciclopirox24$588$25
Doxycycline Monohydrate28$588$21
Fluticasone Propionate18$504$28
Mupirocin41$460$11
Minocycline11$395$36
Cephalexin18$250$14
Mometasone Furoate11$218$20

2017: 31 drugs

Part D drugs prescribed in 2017
Cosentyx Pen (2 Pens)14$55,448$3,961
Fluocinonide480$41,017$85
Otezla13$38,686$2,976
Clobetasol Propionate126$18,663$148
Calcipotriene47$17,864$380
Econazole Nitrate65$11,069$170
Clindamycin Phosphate97$8,039$83
Desonide44$6,575$149
Betamethasone Dipropionate73$6,540$90
Ketoconazole133$6,345$48
Metronidazole46$6,205$135
Fluorouracil23$3,274$142
Triamcinolone Acetonide215$3,155$15
Betamethasone Dipropionate16$2,661$166
Tretinoin32$2,588$81
Doxycycline Hyclate56$2,319$41
Fluocinolone Acetonide17$2,175$128
Hydrocortisone185$1,561$8
Minocycline46$1,366$30
Selenium Sulfide87$1,312$15
Fluocinonide-E11$1,246$113
Clotrimazole45$1,140$25
Imiquimod13$1,127$87
Alclometasone Dipropionate11$990$90
Hydroxyzine33$710$22
Doxycycline Monohydrate28$548$20
Mupirocin60$539$9
Methotrexate11$507$46
Ciclopirox13$408$31
Levocetirizine Dihydrochloride18$263$15
Cephalexin12$78$6

2016: 31 drugs

Part D drugs prescribed in 2016
Fluocinonide535$49,598$93
Clobetasol Propionate187$32,018$171
Econazole Nitrate105$22,890$218
Acitretin16$17,272$1,080
Desonide96$16,064$167
Calcipotriene26$10,702$412
Fluorouracil29$7,008$242
Ketoconazole122$5,851$48
Betamethasone Dipropionate79$5,529$70
Clindamycin Phosphate63$4,950$79
Finacea15$4,133$276
Triamcinolone Acetonide186$3,428$18
Metronidazole26$3,265$126
Doxycycline Hyclate65$3,076$47
Tretinoin33$2,715$82
Fluocinolone Acetonide22$1,999$91
Selenium Sulfide71$1,295$18
Permethrin13$1,267$97
Minocycline34$805$24
Hydrocortisone108$752$7
Doxycycline Monohydrate37$742$20
Ciclopirox21$667$32
Mometasone Furoate25$591$24
Clotrimazole17$433$25
Ipratropium17$393$23
Mupirocin41$390$10
Hydroxyzine28$349$12
Albuterol Sulfate17$337$20
Acyclovir12$131$11
Levocetirizine Dihydrochloride12$101$8
Cephalexin20$99$5

2015: 30 drugs

Part D drugs prescribed in 2015
Fluocinonide500$43,307$87
Clobetasol Propionate181$38,846$215
Econazole Nitrate128$31,889$249
Acitretin22$30,615$1,392
Otezla11$24,263$2,206
Desonide92$16,843$183
Calcipotriene40$15,605$390
Doxycycline Hyclate76$6,171$81
Fluorouracil25$5,461$218
Metronidazole41$4,927$120
Clindamycin Phosphate56$4,464$80
Betamethasone Dipropionate55$3,649$66
Ketoconazole101$3,547$35
Triamcinolone Acetonide188$3,369$18
Finacea13$3,310$255
Desoximetasone16$2,893$181
Tretinoin33$2,882$87
Fluocinolone Acetonide28$2,851$102
Selenium Sulfide88$1,693$19
Permethrin16$1,268$79
Hydrocortisone97$842$9
Mupirocin63$694$11
Minocycline34$677$20
Hydroxyzine35$597$17
Mometasone Furoate30$447$15
Doxycycline Monohydrate23$327$14
Ciclopirox12$301$25
Acyclovir11$135$12
Terbinafine15$120$8
Cephalexin22$103$5

2014: 32 drugs

Part D drugs prescribed in 2014
Enbrel15$51,883$3,459
Fluocinonide465$28,855$62
Desonide120$24,553$205
Calcipotriene46$20,646$449
Acitretin21$19,036$906
Clobetasol Propionate168$11,395$68
Econazole Nitrate138$10,932$79
Metronidazole70$8,639$123
Doxycycline Hyclate56$6,412$114
Tazorac15$5,913$394
Clindamycin Phosphate59$4,588$78
Fluorouracil20$3,674$184
Triamcinolone Acetonide167$3,491$21
Fluocinolone Acetonide29$3,260$112
Imiquimod14$3,165$226
Betamethasone Dipropionate36$2,483$69
Desoximetasone12$2,007$167
Tretinoin37$1,923$52
Ketoconazole73$1,877$26
Acyclovir12$1,299$108
Selenium Sulfide72$1,276$18
Doxycycline Monohydrate25$1,099$44
Mupirocin79$960$12
Hydroxyzine26$515$20
Mometasone Furoate19$496$26
Hydrocortisone55$414$8
Doxepin18$308$17
Minocycline20$292$15
Hydroxychloroquine Sulfate13$287$22
Cimetidine14$211$15
Prednisone14$114$8
Cephalexin15$90$6

2013: 29 drugs

Part D drugs prescribed in 2013
Soriatane23$25,783$1,121
Fluocinonide490$22,858$47
Desonide154$21,521$140
Calcipotriene52$19,386$373
Imiquimod26$8,109$312
Acitretin11$7,640$695
Metronidazole57$7,446$131
Doxycycline Hyclate58$6,169$106
Clobetasol Propionate169$5,826$34
Tazorac13$5,389$415
Clindamycin Phosphate56$5,145$92
Triamcinolone Acetonide185$4,448$24
Econazole Nitrate132$3,960$30
Fluorouracil20$3,678$184
Fluocinolone Acetonide37$3,440$93
Betamethasone Dipropionate41$2,788$68
Ketoconazole116$2,684$23
Hydroxyzine69$1,649$24
Desoximetasone15$1,546$103
Permethrin17$1,430$84
Selenium Sulfide85$1,318$16
Mupirocin94$1,198$13
Tretinoin35$1,042$30
Hydrocortisone51$648$13
Doxycycline Monohydrate22$560$25
Fluticasone Propionate11$429$39
Minocycline19$330$17
Cephalexin24$162$7
Prednisone12$53$4

Money from drug and device companies

$2,827 in 2025

Industry payments by year
202521102$750$2,827
202421159None$3,237
202320117$760$2,847
20221994$5,325$7,247
20211882$4,300$5,667
20201260$5,250$6,096
201918106$17,430$19,782

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AbbvieSkyrizi$1,056
18 payments
  • Meals for Rinvoq · 2025-12-23 · $8
  • Meals for Rinvoq · 2025-12-19 · $27
  • Meals for Skyrizi · 2025-11-19 · $15
  • Meals for Skyrizi · 2025-11-06 · $30
  • Meals for Skyrizi · 2025-09-16 · $11
  • Meals for Skyrizi · 2025-08-15 · $18
  • Meals for Rinvoq · 2025-08-08 · $29
  • Meals for Skyrizi · 2025-07-03 · $11
  • Meals for Skyrizi · 2025-06-24 · $10
  • Meals for Rinvoq · 2025-06-23 · $17
  • Meals for Skyrizi · 2025-05-13 · $8
  • Meals for Skyrizi · 2025-05-01 · $9
  • Meals for Skyrizi · 2025-03-28 · $18
  • Meals for Skyrizi · 2025-03-12 · $23
  • Meals for Skyrizi · 2025-03-06 · $15
  • Consulting · 2025-01-15 · $750
  • Meals for Skyrizi · 2025-01-06 · $30
  • Meals for Skyrizi · 2025-01-02 · $25
LEO PharmaAdbry$311
21 payments
  • Meals for Adbry · 2025-12-15 · $14
  • Meals for Adbry · 2025-12-15 · $14
  • Meals for Adbry · 2025-11-26 · $19
  • Meals for Adbry · 2025-11-17 · $12
  • Meals for Anzupgo · 2025-11-12 · $25
  • Meals for Anzupgo · 2025-10-15 · $26
  • Meals for Adbry · 2025-10-13 · $13
  • Meals for Adbry · 2025-09-30 · $12
  • Meals for Adbry · 2025-09-16 · $3
  • Meals for Adbry · 2025-09-16 · $12
  • Meals for Adbry · 2025-09-05 · $17
  • Meals for Adbry · 2025-08-08 · $26
  • Meals for Adbry · 2025-07-16 · $9
  • Meals for Adbry · 2025-06-20 · $15
  • Meals for Adbry · 2025-06-12 · $12
  • Meals for Adbry · 2025-06-06 · $9
  • Meals for Adbry · 2025-05-22 · $9
  • Meals for Adbry · 2025-05-05 · $25
  • Meals for Adbry · 2025-03-31 · $19
  • Meals for Adbry · 2025-03-13 · $12
  • Meals for Adbry · 2025-02-07 · $10
PfizerCibinqo$276
13 payments
  • Meals for Cibinqo · 2025-10-16 · $21
  • Meals for Cibinqo · 2025-10-14 · $31
  • Meals for Litfulo · 2025-09-03 · $31
  • Meals for Cibinqo · 2025-08-19 · $23
  • Meals for Cibinqo · 2025-07-22 · $13
  • Meals for Litfulo · 2025-07-02 · $7
  • Meals for Cibinqo · 2025-06-26 · $20
  • Meals for Cibinqo · 2025-05-12 · $20
  • Meals for Cibinqo · 2025-05-08 · $29
  • Meals for Cibinqo · 2025-04-23 · $30
  • Meals for Cibinqo · 2025-02-17 · $26
  • Education for Litfulo · 2025-02-14 · $2
  • Meals for Cibinqo · 2025-01-08 · $23
GenzymeDupixent$238
5 payments
  • Meals for Dupixent · 2025-04-24 · $14
  • Meals for Dupixent · 2025-04-03 · $27
  • Meals · 2025-03-18 · $150
  • Meals for Dupixent · 2025-03-12 · $30
  • Meals for Dupixent · 2025-03-11 · $17
Janssen BiotechTremfya$219
7 payments
  • Meals for Tremfya · 2025-06-10 · $10
  • Meals for Tremfya · 2025-04-24 · $14
  • Meals for Tremfya · 2025-03-12 · $2
  • Meals for Tremfya · 2025-03-12 · $14
  • Meals for Tremfya · 2025-03-06 · $150
  • Meals for Tremfya · 2025-01-24 · $17
  • Meals for Tremfya · 2025-01-22 · $11
Novartis PharmaceuticalsRhapsido$127
4 payments
  • Meals for Cosentyx · 2025-12-17 · $34
  • Meals for Rhapsido · 2025-12-09 · $31
  • Meals for Rhapsido · 2025-11-05 · $34
  • Meals for Cosentyx · 2025-09-29 · $28
See all 102 published payments
Every published payment
AbbvieMeals · 2025-12-23Rinvoq$8
AbbvieMeals · 2025-12-19Rinvoq$27
Novartis PharmaceuticalsMeals · 2025-12-17Cosentyx$34
Merck Sharp & DohmeEducation · 2025-12-16None$26
LEO PharmaMeals · 2025-12-15Adbry$14
LEO PharmaMeals · 2025-12-15Adbry$14
Novartis PharmaceuticalsMeals · 2025-12-09Rhapsido$31
Sun Pharmaceutical IndustriesMeals · 2025-12-02Ilumya$33
LEO PharmaMeals · 2025-11-26Adbry$19
AbbvieMeals · 2025-11-19Skyrizi$15
OrganonMeals · 2025-11-18None$18
LEO PharmaMeals · 2025-11-17Adbry$12
LEO PharmaMeals · 2025-11-12Anzupgo$25
AbbvieMeals · 2025-11-06Skyrizi$30
Novartis PharmaceuticalsMeals · 2025-11-05Rhapsido$34
PfizerMeals · 2025-10-16Cibinqo$21
LEO PharmaMeals · 2025-10-15Anzupgo$26
PfizerMeals · 2025-10-14Cibinqo$31
LEO PharmaMeals · 2025-10-13Adbry$13
LEO PharmaMeals · 2025-09-30Adbry$12
Novartis PharmaceuticalsMeals · 2025-09-29Cosentyx$28
UcbMeals · 2025-09-29Bimzelx$19
Sun Pharmaceutical IndustriesMeals · 2025-09-25Ilumya$25
Sun Pharmaceutical IndustriesMeals · 2025-09-24Leqselvi$22
AbbvieMeals · 2025-09-16Skyrizi$11
LEO PharmaMeals · 2025-09-16Adbry$3
LEO PharmaMeals · 2025-09-16Adbry$12
IncyteMeals · 2025-09-05Opzelura$15
LEO PharmaMeals · 2025-09-05Adbry$17
PfizerMeals · 2025-09-03Litfulo$31
Regeneron Healthcare SolutionsMeals · 2025-08-27Dupixent$27
Arcutis BiotherapeuticsMeals · 2025-08-21Zoryve$20
PfizerMeals · 2025-08-19Cibinqo$23
Verrica PharmaceuticalsMeals · 2025-08-18Ycanth$17
AbbvieMeals · 2025-08-15Skyrizi$18
AbbvieMeals · 2025-08-08Rinvoq$29
LEO PharmaMeals · 2025-08-08Adbry$26
OrganonMeals · 2025-08-05None$9
IncyteMeals · 2025-07-30Opzelura$29
PfizerMeals · 2025-07-22Cibinqo$13
LEO PharmaMeals · 2025-07-16Adbry$9
AbbvieMeals · 2025-07-03Skyrizi$11
PfizerMeals · 2025-07-02Litfulo$7
Ortho Dermatologics a division of Bausch Health USMeals · 2025-06-30Siliq$18
PfizerMeals · 2025-06-26Cibinqo$20
AbbvieMeals · 2025-06-24Skyrizi$10
AbbvieMeals · 2025-06-23Rinvoq$17
LEO PharmaMeals · 2025-06-20Adbry$15
STRATA Skin SciencesMeals · 2025-06-17Xtrac$16
LEO PharmaMeals · 2025-06-12Adbry$12
Janssen BiotechMeals · 2025-06-10Tremfya$10
LEO PharmaMeals · 2025-06-06Adbry$9
LEO PharmaMeals · 2025-05-22Adbry$9
Sun Pharmaceutical IndustriesMeals · 2025-05-20Winlevi$25
Janssen Scientific AffairsMeals · 2025-05-14Tremfya$13
E.R. Squibb & Sons L.L.C.Meals · 2025-05-13Sotyktu$21
AbbvieMeals · 2025-05-13Skyrizi$8
PfizerMeals · 2025-05-12Cibinqo$20
PfizerMeals · 2025-05-08Cibinqo$29
LEO PharmaMeals · 2025-05-05Adbry$25
AbbvieMeals · 2025-05-01Skyrizi$9
Regeneron Healthcare SolutionsMeals · 2025-04-30Libtayo$34
Janssen BiotechMeals · 2025-04-24Tremfya$14
GenzymeMeals · 2025-04-24Dupixent$14
PfizerMeals · 2025-04-23Cibinqo$30
E.R. Squibb & Sons L.L.C.Meals · 2025-04-03Sotyktu$19
GenzymeMeals · 2025-04-03Dupixent$27
LEO PharmaMeals · 2025-03-31Adbry$19
AbbvieMeals · 2025-03-28Skyrizi$18
OrganonMeals · 2025-03-20Vtama$7
GenzymeMeals · 2025-03-18None$150
LEO PharmaMeals · 2025-03-13Adbry$12
Janssen BiotechMeals · 2025-03-12Tremfya$2
Janssen BiotechMeals · 2025-03-12Tremfya$14
AbbvieMeals · 2025-03-12Skyrizi$23
GenzymeMeals · 2025-03-12Dupixent$30
GenzymeMeals · 2025-03-11Dupixent$17
E.R. Squibb & Sons L.L.C.Meals · 2025-03-08Sotyktu$30
Janssen BiotechMeals · 2025-03-06Tremfya$150
AbbvieMeals · 2025-03-06Skyrizi$15
AmgenMeals · 2025-03-06Otezla$22
UcbMeals · 2025-02-27Bimzelx$13
PfizerMeals · 2025-02-17Cibinqo$26
STRATA Skin SciencesMeals · 2025-02-17Xtrac$7
PfizerEducation · 2025-02-14Litfulo$2
OrganonMeals · 2025-02-12Vtama$7
OrganonMeals · 2025-02-12Vtama$9
LEO PharmaMeals · 2025-02-07Adbry$10
BiofronteraMeals · 2025-02-03None$15
OrganonMeals · 2025-01-30Vtama$5
OrganonMeals · 2025-01-30Vtama$5
AmgenMeals · 2025-01-29Otezla$19
Janssen BiotechMeals · 2025-01-24Tremfya$17
Lilly USAMeals · 2025-01-23Taltz$15
Janssen BiotechMeals · 2025-01-22Tremfya$11
AbbvieConsulting · 2025-01-15None$750
AmgenMeals · 2025-01-14Otezla$25
PfizerMeals · 2025-01-08Cibinqo$23
OrganonMeals · 2025-01-07Vtama$6
OrganonMeals · 2025-01-07Vtama$9
AbbvieMeals · 2025-01-06Skyrizi$30
AbbvieMeals · 2025-01-02Skyrizi$25
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $3,237

Payments by company in 2024
AbbvieSkyrizi$694
32 payments
  • Meals for Skyrizi · 2024-12-20 · $30
  • Meals · 2024-12-13 · $14
  • Meals for Skyrizi · 2024-12-10 · $9
  • Meals for Skyrizi · 2024-11-22 · $30
  • Meals · 2024-11-22 · $13
  • Meals for Skyrizi · 2024-11-08 · $28
  • Meals for Botox · 2024-10-12 · $23
  • Meals for Skyrizi · 2024-10-09 · $22
  • Meals for Skyrizi · 2024-10-03 · $11
  • Meals for Skyrizi · 2024-09-09 · $26
  • Meals for Rinvoq · 2024-09-05 · $14
  • Meals for Skyrizi · 2024-09-04 · $20
  • Meals for Rinvoq · 2024-08-16 · $25
  • Meals for Botox · 2024-08-03 · $11
  • Meals for Skyrizi · 2024-07-31 · $30
  • Meals for Skyrizi · 2024-06-25 · $30
  • Meals · 2024-06-19 · $34
  • Meals for Skyrizi · 2024-05-23 · $12
  • Meals for Skyrizi · 2024-05-13 · $26
  • Meals for Botox · 2024-05-08 · $16
  • Grant · 2024-04-23 · $30
  • Meals for Rinvoq · 2024-04-10 · $24
  • Meals for Skyrizi · 2024-03-26 · $32
  • Meals for Botox · 2024-03-23 · $21
  • Meals · 2024-03-20 · $11
  • Meals for Skyrizi · 2024-03-12 · $27
  • Meals for Skyrizi · 2024-02-28 · $21
  • Education · 2024-02-28 · $8
  • Meals for Skyrizi · 2024-02-24 · $9
  • Meals for Botox · 2024-02-07 · $32
  • Meals for Rinvoq · 2024-01-24 · $27
  • Meals for Skyrizi · 2024-01-03 · $28
Dermavant SciencesVtama$447
27 payments
  • Meals for Vtama · 2024-12-25 · $5
  • Meals for Vtama · 2024-12-10 · $48
  • Meals for Vtama · 2024-11-19 · $23
  • Meals for Vtama · 2024-11-07 · $7
  • Meals for Vtama · 2024-10-21 · $8
  • Meals for Vtama · 2024-10-21 · $7
  • Meals for Vtama · 2024-10-10 · $10
  • Meals for Vtama · 2024-10-10 · $8
  • Meals for Vtama · 2024-10-04 · $8
  • Meals for Vtama · 2024-10-04 · $10
  • Meals for Vtama · 2024-09-19 · $31
  • Meals for Vtama · 2024-09-17 · $6
  • Meals for Vtama · 2024-08-22 · $14
  • Meals for Vtama · 2024-08-21 · $99
  • Meals for Vtama · 2024-07-31 · $12
  • Meals for Vtama · 2024-07-24 · $2
  • Meals for Vtama · 2024-07-16 · $22
  • Meals for Vtama · 2024-05-30 · $16
  • Meals for Vtama · 2024-04-17 · $1
  • Meals for Vtama · 2024-04-17 · $11
  • Meals for Vtama · 2024-04-05 · $13
  • Meals for Vtama · 2024-03-19 · $11
  • Meals for Vtama · 2024-03-08 · $35
  • Meals for Vtama · 2024-02-27 · $12
  • Meals for Vtama · 2024-02-08 · $12
  • Meals for Vtama · 2024-01-16 · $8
  • Meals for Vtama · 2024-01-10 · $8
Sun Pharmaceutical IndustriesWinlevi$321
7 payments
  • Meals for Ilumya · 2024-10-02 · $29
  • Education · 2024-07-19 · $95
  • Meals for Ilumya · 2024-07-19 · $27
  • Meals for Winlevi · 2024-06-20 · $2
  • Meals for Winlevi · 2024-06-20 · $26
  • Meals for Winlevi · 2024-06-06 · $6
  • Meals for Winlevi · 2024-03-09 · $136
Janssen BiotechTremfya$291
10 payments
  • Meals for Tremfya · 2024-10-25 · $11
  • Meals for Tremfya · 2024-09-09 · $14
  • Meals for Tremfya · 2024-07-12 · $12
  • Education for Tremfya · 2024-07-03 · $100
  • Meals for Tremfya · 2024-04-17 · $20
  • Meals for Tremfya · 2024-04-16 · $8
  • Meals for Tremfya · 2024-04-02 · $12
  • Meals for Tremfya · 2024-03-22 · $8
  • Meals for Tremfya · 2024-02-28 · $26
  • Education for Tremfya · 2024-01-16 · $80
LEO PharmaAdbry$239
22 payments
  • Meals for Adbry · 2024-12-20 · $12
  • Meals for Adbry · 2024-11-25 · $12
  • Meals for Adbry · 2024-11-12 · $15
  • Meals for Adbry · 2024-11-05 · $10
  • Meals for Adbry · 2024-10-24 · $10
  • Meals for Adbry · 2024-10-18 · $10
  • Meals for Adbry · 2024-10-01 · $13
  • Meals for Adbry · 2024-08-26 · $12
  • Meals for Adbry · 2024-08-20 · $15
  • Meals for Adbry · 2024-07-23 · $10
  • Meals for Adbry · 2024-07-15 · $14
  • Meals for Adbry · 2024-07-05 · $8
  • Meals for Adbry · 2024-06-04 · $7
  • Meals for Adbry · 2024-05-20 · $8
  • Meals for Adbry · 2024-05-08 · $10
  • Meals for Adbry · 2024-04-26 · $7
  • Meals for Adbry · 2024-04-12 · $13
  • Meals for Adbry · 2024-04-01 · $12
  • Meals for Adbry · 2024-02-28 · $11
  • Meals for Adbry · 2024-02-22 · $12
  • Meals for Adbry · 2024-02-19 · $12
  • Meals for Adbry · 2024-01-31 · $6
Ortho Dermatologics a division of Bausch Health USCabtreo$212
10 payments
  • Meals for Cabtreo · 2024-12-17 · $22
  • Meals for Cabtreo · 2024-12-04 · $16
  • Meals for Siliq · 2024-12-04 · $25
  • Meals for Cabtreo · 2024-09-18 · $20
  • Meals for Siliq · 2024-08-14 · $22
  • Meals for Siliq · 2024-06-24 · $24
  • Meals for Cabtreo · 2024-06-11 · $22
  • Meals for Cabtreo · 2024-06-11 · $22
  • Meals for Cabtreo · 2024-04-02 · $25
  • Meals for Jublia · 2024-01-11 · $15
AmgenOtezla$209
11 payments
  • Meals for Otezla · 2024-11-21 · $29
  • Meals for Otezla · 2024-08-29 · $26
  • Meals for Otezla · 2024-07-10 · $25
  • Meals for Otezla · 2024-05-21 · $12
  • Meals for Otezla · 2024-04-23 · $21
  • Meals for Otezla · 2024-04-10 · $11
  • Meals for Otezla · 2024-04-10 · $2
  • Meals for Otezla · 2024-03-28 · $18
  • Meals for Otezla · 2024-03-20 · $17
  • Meals for Otezla · 2024-03-12 · $23
  • Meals for Otezla · 2024-02-13 · $25
PfizerEucrisa$156
10 payments
  • Meals for Eucrisa · 2024-12-17 · $20
  • Meals for Cibinqo · 2024-12-11 · $9
  • Meals for Cibinqo · 2024-11-06 · $10
  • Meals for Eucrisa · 2024-10-29 · $21
  • Meals for Eucrisa · 2024-08-27 · $16
  • Meals for Cibinqo · 2024-07-17 · $21
  • Meals for Eucrisa · 2024-06-19 · $19
  • Meals for Cibinqo · 2024-05-30 · $5
  • Meals for Eucrisa · 2024-04-15 · $22
  • Meals for Eucrisa · 2024-02-09 · $12
Arcutis BiotherapeuticsZoryve$117
5 payments
  • Meals for Zoryve · 2024-12-10 · $15
  • Meals for Zoryve · 2024-09-06 · $21
  • Meals for Zoryve · 2024-08-21 · $19
  • Meals for Zoryve · 2024-05-22 · $40
  • Meals for Zoryve · 2024-02-28 · $22
GenzymeDupixent$106
3 payments
  • Meals for Dupixent · 2024-07-30 · $17
  • Meals for Dupixent · 2024-04-09 · $39
  • Meals for Dupixent · 2024-03-14 · $49
Regeneron Healthcare SolutionsDupixent$67
3 payments
  • Meals for Dupixent · 2024-10-16 · $16
  • Meals for Dupixent · 2024-08-23 · $25
  • Meals for Dupixent · 2024-01-31 · $26
E.R. Squibb & Sons L.L.C.Sotyktu$65
3 payments
  • Meals for Sotyktu · 2024-11-13 · $14
  • Meals for Sotyktu · 2024-10-17 · $22
  • Meals for Sotyktu · 2024-03-09 · $30
Galderma Laboratories L.P.Aklief$60
3 payments
  • Meals · 2024-09-17 · $17
  • Meals · 2024-08-28 · $22
  • Meals for Aklief · 2024-06-06 · $22
OrganogenesisPuraply Am$56
2 payments
  • Meals for Puraply Am · 2024-10-15 · $25
  • Meals · 2024-02-15 · $31
UcbBimzelx$53
3 payments
  • Meals for Bimzelx · 2024-11-15 · $18
  • Meals for Bimzelx · 2024-11-04 · $17
  • Meals for Bimzelx · 2024-10-14 · $17
Janssen Research & DevelopmentNone$52
1 payment
  • Meals · 2024-03-09 · $52
Lilly USATaltz$24
1 payment
  • Meals for Taltz · 2024-12-09 · $24
STRATA Skin SciencesXtrac$22
1 payment
  • Meals for Xtrac · 2024-04-16 · $22
Janssen Scientific AffairsTremfya$21
1 payment
  • Meals for Tremfya · 2024-07-30 · $21
IncyteOpzelura$13
1 payment
  • Meals for Opzelura · 2024-07-02 · $13
BiofronteraAmeluz$13
3 payments
  • Meals for Ameluz · 2024-11-20 · $8
  • Meals for Ameluz · 2024-11-20 · $2
  • Meals for Ameluz · 2024-11-20 · $3

2023: $2,847

Payments by company in 2023
LEO Pharma ASNone$760
1 payment
  • Consulting · 2023-08-30 · $760
LEO PharmaAdbry$423
30 payments
  • Meals for Adbry · 2023-12-12 · $5
  • Meals for Adbry · 2023-12-12 · $12
  • Meals for Adbry · 2023-10-20 · $12
  • Meals for Adbry · 2023-10-10 · $11
  • Meals for Adbry · 2023-09-27 · $9
  • Meals for Adbry · 2023-09-23 · $12
  • Meals for Adbry · 2023-09-08 · $10
  • Meals for Adbry · 2023-09-06 · $7
  • Meals for Adbry · 2023-08-14 · $10
  • Meals for Adbry · 2023-08-03 · $14
  • Meals for Adbry · 2023-07-27 · $12
  • Meals for Adbry · 2023-07-22 · $12
  • Meals for Adbry · 2023-07-10 · $9
  • Meals for Adbry · 2023-06-26 · $9
  • Meals for Adbry · 2023-06-20 · $13
  • Meals for Adbry · 2023-06-13 · $16
  • Meals for Adbry · 2023-05-24 · $11
  • Meals for Adbry · 2023-05-17 · $7
  • Meals for Adbry · 2023-05-16 · $9
  • Meals for Adbry · 2023-05-08 · $13
  • Meals for Adbry · 2023-04-26 · $11
  • Meals for Adbry · 2023-04-17 · $10
  • Meals for Adbry · 2023-04-17 · $5
  • Meals for Adbry · 2023-04-14 · $14
  • Meals for Adbry · 2023-04-10 · $12
  • Meals for Adbry · 2023-03-25 · $7
  • Meals · 2023-03-16 · $124
  • Meals for Adbry · 2023-03-01 · $11
  • Meals for Adbry · 2023-02-22 · $6
  • Meals for Adbry · 2023-01-31 · $8
AbbVieSkyrizi$239
13 payments
  • Meals for Skyrizi · 2023-11-15 · $30
  • Meals for Rinvoq · 2023-10-24 · $8
  • Meals · 2023-09-12 · $24
  • Meals for Skyrizi · 2023-09-01 · $26
  • Meals for Skyrizi · 2023-08-26 · $27
  • Meals for Humira · 2023-08-14 · $20
  • Meals for Rinvoq · 2023-08-08 · $20
  • Meals for Skyrizi · 2023-07-17 · $18
  • Meals · 2023-05-23 · $6
  • Meals for Skyrizi · 2023-05-22 · $22
  • Meals for Skyrizi · 2023-04-06 · $16
  • Meals · 2023-02-24 · $11
  • Meals · 2023-01-31 · $12
Dermavant SciencesVtama$237
10 payments
  • Meals for Vtama · 2023-12-20 · $8
  • Meals for Vtama · 2023-12-10 · $8
  • Meals for Vtama · 2023-12-07 · $81
  • Meals for Vtama · 2023-11-18 · $6
  • Meals for Vtama · 2023-11-18 · $11
  • Meals for Vtama · 2023-11-10 · $11
  • Meals for Vtama · 2023-10-11 · $11
  • Meals for Vtama · 2023-09-21 · $28
  • Meals for Vtama · 2023-09-14 · $9
  • Meals for Vtama · 2023-08-09 · $64
Lilly USATaltz$171
12 payments
  • Meals for Taltz · 2023-11-08 · $12
  • Meals for Taltz · 2023-08-24 · $1
  • Meals for Taltz · 2023-08-24 · $10
  • Meals for Taltz · 2023-08-15 · $24
  • Meals for Taltz · 2023-07-14 · $12
  • Meals for Taltz · 2023-06-20 · $27
  • Meals for Taltz · 2023-05-30 · $16
  • Meals for Taltz · 2023-05-24 · $18
  • Meals for Taltz · 2023-05-24 · $13
  • Meals for Taltz · 2023-04-18 · $18
  • Meals for Taltz · 2023-02-07 · $0
  • Meals for Taltz · 2023-02-07 · $18
Galderma Laboratories L.P.Epiduo$166
5 payments
  • Meals · 2023-06-01 · $3
  • Meals for Epiduo · 2023-03-21 · $101
  • Meals · 2023-03-08 · $18
  • Meals · 2023-02-15 · $21
  • Meals · 2023-01-11 · $23
Ortho Dermatologics a division of Bausch Health USJublia$143
9 payments
  • Meals for Jublia · 2023-11-27 · $23
  • Education for Duobrii · 2023-11-02 · $7
  • Meals for Siliq · 2023-10-23 · $20
  • Meals for Siliq · 2023-10-23 · $21
  • Meals for Jublia · 2023-09-25 · $17
  • Meals for Siliq · 2023-06-12 · $15
  • Meals for Arazlo · 2023-06-07 · $15
  • Education for Arazlo · 2023-05-09 · $7
  • Meals for Jublia · 2023-03-15 · $19
Janssen BiotechTremfya$136
6 payments
  • Meals for Tremfya · 2023-12-20 · $27
  • Meals for Tremfya · 2023-09-19 · $25
  • Meals for Tremfya · 2023-09-07 · $28
  • Meals for Tremfya · 2023-07-31 · $18
  • Meals for Remicade · 2023-02-21 · $23
  • Meals for Remicade · 2023-01-18 · $14
Novartis PharmaceuticalsCosentyx$131
4 payments
  • Meals · 2023-07-18 · $34
  • Meals for Cosentyx · 2023-03-28 · $34
  • Meals for Cosentyx · 2023-02-22 · $31
  • Meals for Cosentyx · 2023-01-18 · $32
PfizerEucrisa$112
11 payments
  • Meals for Eucrisa · 2023-11-10 · $21
  • Meals for Eucrisa · 2023-10-19 · $8
  • Meals for Eucrisa · 2023-10-07 · $7
  • Meals for Eucrisa · 2023-09-14 · $2
  • Meals for Eucrisa · 2023-08-17 · $5
  • Meals for Eucrisa · 2023-08-17 · $5
  • Meals for Eucrisa · 2023-08-17 · $2
  • Meals for Eucrisa · 2023-08-02 · $27
  • Education for Cibinqo · 2023-04-18 · $15
  • Meals for Eucrisa · 2023-03-28 · $4
  • Education for Cibinqo · 2023-03-27 · $15
Sun Pharmaceutical IndustriesIlumya$49
2 payments
  • Meals for Winlevi · 2023-06-02 · $15
  • Meals for Ilumya · 2023-03-19 · $34
Arcutis BiotherapeuticsNone$44
2 payments
  • Meals · 2023-03-28 · $20
  • Meals · 2023-01-26 · $24
AmgenOtezla$43
2 payments
  • Meals for Otezla · 2023-12-19 · $16
  • Meals for Otezla · 2023-02-28 · $28
E.R. Squibb & Sons L.L.C.Sotyktu$41
2 payments
  • Meals for Sotyktu · 2023-10-18 · $23
  • Meals for Sotyktu · 2023-03-08 · $18
BiofronteraAmeluz$39
3 payments
  • Meals for Ameluz · 2023-11-29 · $7
  • Meals for Ameluz · 2023-10-16 · $15
  • Meals for Ameluz · 2023-04-26 · $17
UcbNone$30
1 payment
  • Meals · 2023-03-19 · $30
Janssen Research & DevelopmentNone$26
1 payment
  • Meals · 2023-03-17 · $26
Regeneron Healthcare SolutionsDupixent$22
1 payment
  • Meals for Dupixent · 2023-07-12 · $22
OrganogenesisPuraply$21
1 payment
  • Meals for Puraply · 2023-05-03 · $21
STRATA Skin SciencesXtrac$16
1 payment
  • Meals for Xtrac · 2023-08-29 · $16

2022: $7,247

Payments by company in 2022
AbbvieSkyrizi$4,709
33 payments
  • Meals for Rinvoq · 2022-12-13 · $18
  • Meals for Skyrizi · 2022-12-13 · $25
  • Consulting · 2022-11-14 · $1,125
  • Meals for Rinvoq · 2022-11-07 · $8
  • Meals for Skyrizi · 2022-10-31 · $18
  • Meals for Skyrizi · 2022-10-11 · $18
  • Consulting · 2022-08-26 · $750
  • Consulting · 2022-08-26 · $750
  • Meals for Humira · 2022-08-17 · $24
  • Meals for Skyrizi · 2022-07-13 · $23
  • Meals for Skyrizi · 2022-07-11 · $22
  • Meals for Humira · 2022-06-22 · $24
  • Meals for Skyrizi · 2022-06-13 · $23
  • Meals for Skyrizi · 2022-06-08 · $27
  • Meals for Humira · 2022-05-18 · $22
  • Meals for Skyrizi · 2022-05-16 · $16
  • Meals for Skyrizi · 2022-05-12 · $24
  • Meals for Skyrizi · 2022-05-11 · $18
  • Consulting · 2022-05-03 · $750
  • Meals for Skyrizi · 2022-04-28 · $16
  • Meals for Humira · 2022-04-20 · $22
  • Meals for Skyrizi · 2022-04-19 · $21
  • Meals for Skyrizi · 2022-04-13 · $22
  • Meals for Rinvoq · 2022-03-30 · $26
  • Meals for Skyrizi · 2022-03-28 · $25
  • Consulting · 2022-03-22 · $750
  • Travel · 2022-03-22 · $17
  • Meals for Skyrizi · 2022-03-16 · $20
  • Meals for Skyrizi · 2022-03-14 · $12
  • Meals for Skyrizi · 2022-02-22 · $18
  • Meals for Humira · 2022-02-21 · $24
  • Meals for Skyrizi · 2022-01-26 · $22
  • Meals for Humira · 2022-01-19 · $28
Eli Lilly andNone$1,200
1 payment
  • Consulting · 2022-04-26 · $1,200
Janssen BiotechRemicade$196
13 payments
  • Meals for Tremfya · 2022-12-13 · $6
  • Meals for Remicade · 2022-11-29 · $2
  • Meals for Remicade · 2022-11-29 · $24
  • Meals for Remicade · 2022-11-29 · $2
  • Meals for Remicade · 2022-11-29 · $24
  • Meals for Remicade · 2022-11-23 · $32
  • Meals for Remicade · 2022-11-23 · $32
  • Meals for Tremfya · 2022-11-14 · $28
  • Meals for Remicade · 2022-10-05 · $14
  • Meals for Tremfya · 2022-08-02 · $7
  • Meals for Tremfya · 2022-07-12 · $9
  • Meals for Tremfya · 2022-06-14 · $8
  • Meals for Tremfya · 2022-03-08 · $8
LEO PharmaAdbry$192
16 payments
  • Meals for Adbry · 2022-12-07 · $9
  • Meals for Adbry · 2022-12-02 · $13
  • Meals for Adbry · 2022-11-28 · $8
  • Meals for Adbry · 2022-11-11 · $27
  • Meals for Adbry · 2022-10-28 · $6
  • Meals for Adbry · 2022-10-25 · $10
  • Meals for Adbry · 2022-08-29 · $14
  • Meals for Adbry · 2022-08-16 · $11
  • Meals for Adbry · 2022-07-29 · $28
  • Meals for Adbry · 2022-07-07 · $10
  • Meals for Adbry · 2022-07-01 · $9
  • Meals for Adbry · 2022-01-18 · $13
  • Meals for Adbry · 2022-01-18 · $15
  • Meals for Adbry · 2022-01-12 · $7
  • Meals for Adbry · 2022-01-12 · $6
  • Meals for Adbry · 2022-01-12 · $5
Galderma Laboratories L.P.None$191
1 payment
  • Meals · 2022-03-30 · $191
Ortho Dermatologics a division of Bausch Health USSiliq$152
6 payments
  • Meals for Siliq · 2022-12-05 · $25
  • Meals for Siliq · 2022-09-21 · $25
  • Meals for Siliq · 2022-07-27 · $23
  • Meals · 2022-04-22 · $43
  • Meals for Siliq · 2022-02-23 · $16
  • Meals for Jublia · 2022-01-26 · $20
Acrotech BiopharmaNone$103
1 payment
  • Meals · 2022-10-27 · $103
Novartis PharmaceuticalsCosentyx$98
4 payments
  • Meals for Xolair · 2022-10-19 · $23
  • Meals for Cosentyx · 2022-06-14 · $25
  • Meals for Cosentyx · 2022-05-09 · $25
  • Meals for Cosentyx · 2022-04-05 · $25
Regeneron Healthcare SolutionsDupixent$64
3 payments
  • Meals for Dupixent · 2022-08-10 · $25
  • Meals for Dupixent · 2022-05-04 · $22
  • Meals for Dupixent · 2022-02-16 · $16
Lilly USATaltz$62
4 payments
  • Meals for Taltz · 2022-11-22 · $11
  • Meals for Taltz · 2022-08-23 · $13
  • Meals for Taltz · 2022-07-19 · $22
  • Meals for Taltz · 2022-06-28 · $17
PfizerCibinqo$56
2 payments
  • Meals for Eucrisa · 2022-12-01 · $25
  • Meals for Cibinqo · 2022-02-01 · $30
STRATA Skin SciencesXtrac$41
1 payment
  • Meals for Xtrac · 2022-06-21 · $41
GenzymeDupixent$39
2 payments
  • Meals for Dupixent · 2022-09-28 · $15
  • Meals for Dupixent · 2022-02-02 · $24
AllerganBotox$39
2 payments
  • Meals for Botox · 2022-09-27 · $25
  • Meals for Botox · 2022-04-02 · $14
Sun Pharmaceutical IndustriesIlumya$26
1 payment
  • Meals for Ilumya · 2022-11-22 · $26
Journey MedicalQbrexza$23
1 payment
  • Meals for Qbrexza · 2022-10-06 · $23
EPI HealthCloderm$20
1 payment
  • Meals for Cloderm · 2022-01-31 · $20
IncyteOpzelura$19
1 payment
  • Meals for Opzelura · 2022-03-27 · $19
AmgenOtezla$18
1 payment
  • Meals for Otezla · 2022-02-15 · $18

2021: $5,667

Payments by company in 2021
Eli Lilly andNone$2,300
1 payment
  • Consulting · 2021-07-15 · $2,300
Ortho Dermatologics a division of Bausch Health USArazlo$1,331
11 payments
  • Meals for Jublia · 2021-12-15 · $5
  • Meals for Duobrii · 2021-08-25 · $24
  • Meals for Duobrii · 2021-06-07 · $6
  • Gift · 2021-06-03 · $8
  • Meals for Arazlo · 2021-06-01 · $21
  • Meals for Duobrii · 2021-05-20 · $21
  • Meals for Arazlo · 2021-05-10 · $1
  • Meals for Arazlo · 2021-05-10 · $24
  • Meals for Duobrii · 2021-03-24 · $5
  • Paid to speak or teach for Arazlo · 2021-03-23 · $1,200
  • Meals for Duobrii · 2021-03-15 · $16
AlmirallKlisyri$842
4 payments
  • Meals for Seysara · 2021-05-19 · $19
  • Education · 2021-04-07 · $11
  • Consulting for Klisyri · 2021-03-17 · $800
  • Meals for Seysara · 2021-01-20 · $13
AbbVieSkyrizi$349
19 payments
  • Meals for Humira · 2021-12-07 · $28
  • Meals for Skyrizi · 2021-12-06 · $14
  • Meals for Humira · 2021-11-10 · $21
  • Meals for Skyrizi · 2021-11-10 · $20
  • Meals for Humira · 2021-10-28 · $4
  • Meals for Humira · 2021-10-27 · $24
  • Meals for Humira · 2021-10-19 · $29
  • Meals for Skyrizi · 2021-10-13 · $23
  • Meals for Humira · 2021-08-11 · $24
  • Meals for Skyrizi · 2021-08-10 · $21
  • Meals for Skyrizi · 2021-07-15 · $16
  • Meals for Skyrizi · 2021-07-14 · $2
  • Meals for Skyrizi · 2021-07-13 · $20
  • Meals for Skyrizi · 2021-05-26 · $20
  • Meals · 2021-05-12 · $20
  • Meals for Humira · 2021-04-30 · $28
  • Meals for Skyrizi · 2021-04-16 · $3
  • Meals for Skyrizi · 2021-04-06 · $18
  • Meals for Skyrizi · 2021-03-10 · $13
Sun Pharmaceutical IndustriesAbsorica Ld$158
14 payments
  • Meals for Winlevi · 2021-11-11 · $10
  • Meals for Absorica Ld · 2021-10-18 · $8
  • Meals for Absorica Ld · 2021-10-07 · $6
  • Meals for Absorica Ld · 2021-09-17 · $11
  • Meals for Ilumya · 2021-09-13 · $25
  • Meals for Absorica Ld · 2021-08-26 · $7
  • Meals for Absorica Ld · 2021-08-18 · $13
  • Meals for Absorica Ld · 2021-07-19 · $16
  • Meals for Absorica Ld · 2021-07-07 · $11
  • Meals for Absorica Ld · 2021-06-16 · $8
  • Meals for Absorica Ld · 2021-05-25 · $11
  • Meals for Absorica Ld · 2021-05-14 · $6
  • Meals for Absorica Ld · 2021-05-05 · $16
  • Meals for Absorica Ld · 2021-04-12 · $11
Lilly USATaltz$137
6 payments
  • Meals for Taltz · 2021-11-19 · $16
  • Meals for Taltz · 2021-11-01 · $22
  • Meals for Taltz · 2021-09-22 · $25
  • Meals for Taltz · 2021-06-22 · $17
  • Meals for Taltz · 2021-03-23 · $31
  • Meals for Taltz · 2021-02-09 · $26
PfizerEucrisa$106
5 payments
  • Meals for Eucrisa · 2021-12-01 · $35
  • Meals for Eucrisa · 2021-07-26 · $7
  • Meals for Eucrisa · 2021-06-01 · $23
  • Meals for Eucrisa · 2021-03-09 · $19
  • Meals for Eucrisa · 2021-01-12 · $22
VYNE PharmaceuticalsAmzeeq$82
4 payments
  • Meals for Amzeeq · 2021-08-03 · $24
  • Meals for Amzeeq · 2021-04-09 · $15
  • Meals for Amzeeq · 2021-03-17 · $21
  • Meals for Amzeeq · 2021-01-08 · $22
OrganogenesisPuraply Antimicrobial$80
3 payments
  • Meals for Puraply Antimicrobial · 2021-10-18 · $33
  • Meals for Puraply · 2021-09-17 · $14
  • Meals for Puraply Antimicrobial · 2021-06-21 · $34
LEO PharmaEnstilar$50
3 payments
  • Meals for Enstilar · 2021-05-05 · $17
  • Meals for Enstilar · 2021-04-28 · $16
  • Meals for Enstilar · 2021-03-02 · $16
Regeneron Healthcare SolutionsDupixent$49
2 payments
  • Meals for Dupixent · 2021-07-21 · $30
  • Meals for Dupixent · 2021-06-30 · $19
Janssen BiotechRemicade$45
3 payments
  • Meals for Tremfya · 2021-11-22 · $21
  • Meals for Remicade · 2021-09-29 · $12
  • Meals for Remicade · 2021-07-02 · $13
Bausch Health USNone$45
1 payment
  • Meals · 2021-06-03 · $45
Galderma Laboratories L.P.Oracea$30
2 payments
  • Meals for Oracea · 2021-03-17 · $18
  • Meals for Oracea · 2021-01-06 · $12
Mayne PharmaNone$19
1 payment
  • Meals · 2021-08-24 · $19
AllerganBotox$17
1 payment
  • Meals for Botox · 2021-11-24 · $17
IncyteOpzelura$14
1 payment
  • Meals for Opzelura · 2021-11-29 · $14
EPI HealthCloderm$13
1 payment
  • Meals for Cloderm · 2021-02-23 · $13

2020: $6,096

Payments by company in 2020
PfizerEucrisa$3,460
9 payments
  • Meals for Eucrisa · 2020-12-15 · $11
  • Paid to speak or teach for Eucrisa · 2020-12-10 · $2,525
  • Meals for Eucrisa · 2020-09-15 · $27
  • Meals for Eucrisa · 2020-08-18 · $19
  • Paid to speak or teach for Eucrisa · 2020-06-02 · $825
  • Meals for Eucrisa · 2020-03-10 · $6
  • Meals for Eucrisa · 2020-02-20 · $14
  • Meals for Eucrisa · 2020-01-31 · $25
  • Meals for Eucrisa · 2020-01-06 · $8
Journey MedicalNone$1,500
2 payments
  • Consulting · 2020-12-28 · $500
  • Consulting · 2020-12-28 · $1,000
Ortho Dermatologics a division of Bausch Health USArazlo$549
12 payments
  • Meals for Duobrii · 2020-12-02 · $22
  • Meals for Duobrii · 2020-11-16 · $18
  • Meals for Duobrii · 2020-11-04 · $16
  • Meals for Duobrii · 2020-10-21 · $6
  • Meals for Duobrii · 2020-09-30 · $4
  • Meals for Duobrii · 2020-09-02 · $4
  • Meals for Arazlo · 2020-09-02 · $18
  • Meals for Duobrii · 2020-08-12 · $11
  • Paid to speak or teach for Arazlo · 2020-08-04 · $400
  • Meals for Duobrii · 2020-05-11 · $28
  • Meals for Duobrii · 2020-03-04 · $8
  • Meals for Duobrii · 2020-01-29 · $14
AbbVieSkyrizi$122
6 payments
  • Meals for Skyrizi · 2020-10-28 · $21
  • Meals for Humira · 2020-10-07 · $23
  • Meals for Skyrizi · 2020-10-06 · $19
  • Meals for Skyrizi · 2020-04-29 · $17
  • Meals for Skyrizi · 2020-03-13 · $24
  • Meals for Humira · 2020-01-24 · $19
LEO PharmaEnstilar$119
14 payments
  • Meals for Enstilar · 2020-12-22 · $8
  • Meals for Enstilar · 2020-12-17 · $8
  • Meals for Enstilar · 2020-12-01 · $8
  • Meals for Enstilar · 2020-11-17 · $6
  • Meals for Enstilar · 2020-11-10 · $8
  • Meals for Enstilar · 2020-10-23 · $9
  • Meals for Enstilar · 2020-10-07 · $7
  • Meals for Enstilar · 2020-09-25 · $6
  • Meals for Enstilar · 2020-09-17 · $6
  • Meals for Enstilar · 2020-08-24 · $8
  • Meals for Enstilar · 2020-07-27 · $9
  • Meals for Finacea · 2020-06-11 · $5
  • Meals for Finacea · 2020-05-07 · $25
  • Meals for Enstilar · 2020-03-03 · $7
AmgenOtezla$92
4 payments
  • Meals for Enbrel · 2020-09-22 · $17
  • Meals for Otezla · 2020-04-22 · $22
  • Meals for Otezla · 2020-03-05 · $32
  • Meals for Enbrel · 2020-02-13 · $21
Sun Pharmaceutical IndustriesAbsorica Ld$68
4 payments
  • Meals for Absorica Ld · 2020-12-07 · $16
  • Meals for Absorica Ld · 2020-09-04 · $12
  • Meals for Absorica Ld · 2020-02-26 · $20
  • Meals for Absorica Ld · 2020-02-07 · $20
Mayne PharmaDoryx$55
3 payments
  • Meals for Doryx · 2020-05-02 · $15
  • Meals for Doryx · 2020-02-04 · $20
  • Meals for Doryx · 2020-01-16 · $19
BiofronteraAmeluz$39
2 payments
  • Meals for Ameluz · 2020-08-10 · $19
  • Meals for Ameluz · 2020-01-29 · $20
Lilly USATaltz$37
2 payments
  • Meals for Taltz · 2020-11-17 · $14
  • Meals for Taltz · 2020-01-21 · $23
EPI HealthSitavig$31
1 payment
  • Meals for Sitavig · 2020-10-13 · $31
DermiraQbrexza$23
1 payment
  • Meals for Qbrexza · 2020-10-21 · $23

2019: $19,782

Payments by company in 2019
DermiraQbrexza$7,884
9 payments
  • Travel for Qbrexza · 2019-11-12 · $106
  • Honoraria for Qbrexza · 2019-11-12 · $2,500
  • Travel for Qbrexza · 2019-11-12 · $20
  • Meals for Qbrexza · 2019-11-12 · $124
  • Meals · 2019-10-30 · $8
  • Travel for Qbrexza · 2019-10-17 · $106
  • Travel for Qbrexza · 2019-09-11 · $20
  • Honoraria for Qbrexza · 2019-03-18 · $2,500
  • Consulting for Qbrexza · 2019-01-08 · $2,500
Mayne PharmaLexette$7,503
12 payments
  • Meals for Doryx · 2019-11-26 · $26
  • Meals for Doryx · 2019-07-03 · $28
  • Meals for Doryx · 2019-06-06 · $16
  • Meals for Doryx · 2019-06-05 · $3
  • Honoraria for Fabior · 2019-05-10 · $605
  • Honoraria for Lexette · 2019-04-26 · $605
  • Honoraria for Lexette · 2019-04-18 · $605
  • Honoraria for Lexette · 2019-04-08 · $650
  • Meals for Doryx · 2019-03-01 · $26
  • Meals for Doryx · 2019-01-16 · $27
  • Honoraria for Lexette · 2019-01-03 · $4,840
  • Travel for Lexette · 2019-01-03 · $73
PfizerEucrisa$2,862
12 payments
  • Meals for Eucrisa · 2019-12-16 · $17
  • Meals for Eucrisa · 2019-12-16 · $1
  • Meals for Eucrisa · 2019-10-30 · $5
  • Meals for Eucrisa · 2019-06-11 · $22
  • Meals for Eucrisa · 2019-04-16 · $2
  • Meals for Eucrisa · 2019-04-16 · $20
  • Meals for Eucrisa · 2019-04-09 · $5
  • Meals for Eucrisa · 2019-03-20 · $16
  • Paid to speak or teach for Eucrisa · 2019-02-15 · $2,625
  • Meals for Eucrisa · 2019-02-12 · $15
  • Meals for Eucrisa · 2019-02-12 · $130
  • Meals for Eucrisa · 2019-01-15 · $5
Ortho Dermatologics a division of Bausch Health USBryhali$472
20 payments
  • Meals for Duobrii · 2019-12-24 · $10
  • Meals for Siliq · 2019-12-24 · $14
  • Meals for Duobrii · 2019-12-05 · $15
  • Meals for Siliq · 2019-12-05 · $58
  • Meals for Bryhali · 2019-10-08 · $21
  • Meals for Bryhali · 2019-10-08 · $0
  • Meals for Duobrii · 2019-09-30 · $12
  • Meals for Duobrii · 2019-09-30 · $10
  • Meals for Duobrii · 2019-09-30 · $9
  • Meals for Siliq · 2019-09-16 · $16
  • Meals for Duobrii · 2019-09-16 · $7
  • Meals for Siliq · 2019-09-05 · $44
  • Meals for Siliq · 2019-09-04 · $6
  • Meals for Bryhali · 2019-05-13 · $6
  • Meals for Siliq · 2019-05-13 · $3
  • Meals for Bryhali · 2019-05-13 · $20
  • Meals for Bryhali · 2019-05-02 · $170
  • Meals for Bryhali · 2019-04-15 · $20
  • Meals for Siliq · 2019-02-21 · $19
  • Meals for Siliq · 2019-01-30 · $13
AbbVieHumira$226
11 payments
  • Meals for Humira · 2019-11-21 · $22
  • Meals for Humira · 2019-10-25 · $15
  • Meals for Humira · 2019-09-11 · $19
  • Meals for Humira · 2019-08-06 · $24
  • Meals for Skyrizi · 2019-07-09 · $25
  • Meals for Humira · 2019-06-26 · $21
  • Meals for Humira · 2019-06-07 · $20
  • Meals for Skyrizi · 2019-05-03 · $20
  • Meals for Humira · 2019-04-30 · $20
  • Meals for Humira · 2019-04-20 · $20
  • Meals for Humira · 2019-01-04 · $21
AlmirallNone$150
2 payments
  • Meals · 2019-03-02 · $72
  • Meals · 2019-03-02 · $78
Janssen BiotechTremfya$129
10 payments
  • Meals for Tremfya · 2019-09-03 · $7
  • Meals for Tremfya · 2019-07-23 · $10
  • Meals for Tremfya · 2019-07-23 · $0
  • Meals for Tremfya · 2019-06-22 · $11
  • Meals for Tremfya · 2019-05-14 · $20
  • Meals for Tremfya · 2019-04-02 · $10
  • Meals for Tremfya · 2019-03-22 · $6
  • Meals for Tremfya · 2019-03-19 · $19
  • Meals for Tremfya · 2019-03-11 · $25
  • Meals for Tremfya · 2019-02-08 · $22
AmgenEnbrel$82
5 payments
  • Meals for Enbrel · 2019-10-22 · $12
  • Meals for Enbrel · 2019-09-24 · $32
  • Meals for Enbrel · 2019-08-27 · $12
  • Meals for Enbrel · 2019-07-30 · $15
  • Meals for Enbrel · 2019-05-21 · $11
Novartis PharmaceuticalsCosentyx$81
4 payments
  • Meals for Cosentyx · 2019-09-25 · $18
  • Meals for Cosentyx · 2019-06-24 · $21
  • Meals for Cosentyx · 2019-05-06 · $21
  • Meals for Cosentyx · 2019-01-28 · $20
BiofronteraAmeluz$80
4 payments
  • Meals for Ameluz · 2019-12-17 · $19
  • Meals for Ameluz · 2019-10-15 · $20
  • Meals for Ameluz · 2019-07-29 · $22
  • Meals for Ameluz · 2019-06-18 · $19
Lilly USATaltz$75
3 payments
  • Meals for Taltz · 2019-09-17 · $18
  • Meals for Taltz · 2019-07-18 · $33
  • Meals for Taltz · 2019-05-06 · $23
Sun Pharmaceutical IndustriesIlumya$65
3 payments
  • Meals for Ilumya · 2019-07-16 · $23
  • Meals for Ilumya · 2019-05-16 · $23
  • Meals for Ilumya · 2019-03-28 · $19
Galderma Laboratories L.P.Epiduo Forte$42
3 payments
  • Meals for Epiduo Forte · 2019-11-12 · $14
  • Meals for Epiduo Forte · 2019-10-16 · $14
  • Meals for Epiduo Forte · 2019-02-27 · $14
EPI HealthSitavig$37
3 payments
  • Meals for Sitavig · 2019-04-26 · $8
  • Meals for Sitavig · 2019-04-25 · $19
  • Meals for Sitavig · 2019-01-16 · $10
DUSA PharmaceuticalsLevulan Kerastick$30
2 payments
  • Meals for Blu-U · 2019-11-06 · $11
  • Meals for Levulan Kerastick · 2019-03-26 · $19
Regeneron Healthcare SolutionsDupixent$23
1 payment
  • Meals for Dupixent · 2019-09-11 · $23
CelgeneOtezla$21
1 payment
  • Meals for Otezla · 2019-11-06 · $21
Promius PharmaSernivo$20
1 payment
  • Meals for Sernivo · 2019-03-20 · $20

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Allergan, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy in Subjects With Glabellar Frown Lines · 2020Their institution$361,467
Amgen Inc. · Interchangeability Study - Abp 654 · 2021Their institution$218,258
Eli Lilly and Company · A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab To Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis · 2019Their institution$213,525
Takeda Pharmaceuticals U.S.A., Inc. · A Study About How Well Tak-279 Works and Its Safety in Participants With Moderate-To-Severe Plaque Psoriasis During 52 Weeks of Treatment · 2024Their institution$127,751
Vanda Pharmaceuticals Inc. · An Open Label, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Trichostatin A in Healthy Volunteers · 2024Their institution$116,983
Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2025Their institution$109,897
Kiniksa Pharmaceuticals, Ltd. · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2021Their institution$102,201
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2020Their institution$100,338
Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2024Their institution$89,857
Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over A 68-Week Treatment Period in Adult Patients With Moderate To Severe Hidradenitis Sup · 2025Their institution$89,177
Incyte Corporation · True Ad2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis · 2019Their institution$75,985
Takeda Pharmaceuticals U.S.A., Inc. · Tak-279-Pso-3003 A Phase 3, Multi-Center, Open-Label Study To Evaluate the Efficacy, Safety, and Tolerability of Tak-279 in Subjects With Moderate To Severe Plaque Psoriasis · 2025Their institution$74,504
Eli Lilly and Company · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of Ly4100511 (Dc-853) for the Treatment of Adult Participants With Moderate-To Severe Plaque Psoriasis · 2025Their institution$74,418
SANOFI US SERVICES INC. · A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group 48-Week Extension Study To Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered As Monotherapy By Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-To-Severe Atopic Dermatitis · 2025Their institution$72,770
Vanda Pharmaceuticals Inc. · An Open Label Study Evaluating the Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild To Severe Onychomycosis · 2025Their institution$71,175
Janssen Research & Development, LLC · A Phase 2a2b Multi Center Randomized Placebo and Active Comparator Controlled Double Blind Dose Ranging Study To Evaluate the Safety and Efficacy of Bermekimab Jnj77474462 for the Treatment of Subjects With Moderate To Severe Hidradenitis Suppurativa. · 2022Their institution$69,126
Incyte Corporation · Pd Effects and Predictive Biomarkers of Jak/Stat Inhibition With Ruxolitinib in Operable Head and Neck Squamous Cell Carcinoma-A Window of Opportunity Trial · 2020Their institution$65,066
Acrotech Biopharma Inc. · 2023Their institution$62,101
Teva Pharmaceuticals USA, Inc. · A Phase 1b, Open-Label Trial To Assess Safety and Exploratory Efficacy of Tev-53408 in Participants With Vitiligo · 2025Their institution$61,022
Sun Pharmaceutical Industries Inc. · A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study To Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate To Severe Plaque Psoriasis of the Scalp · 2020Their institution$60,496
Takeda Pharmaceuticals U.S.A., Inc. · A Study About How Well Tak-279 Works and Its Safety in Participants With Moderate-To-Severe Plaque Psoriasis During 52 Weeks of Treatment · 2025Their institution$59,937
Regeneron Pharmaceuticals, Inc. · An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-To-Severe Atopic Dermatitis · 2023Their institution$59,741
Eli Lilly and Company · An Open-Label 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2023Their institution$57,971
Incyte Corporation · A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of Incb053914 in Combination With Incb050465 in Participants With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma · 2020Their institution$56,694
Janssen Research & Development, LLC · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Jnj-77242113 for the Treatment of Participants With Moderate To Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment · 2024Their institution$55,753
Bausch Health US, LLC · Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study · 2019Their institution$55,499
Novartis Pharmaceuticals Corporation · A Randomized Subject and Investigator Blinded Placebo Controlled Multi Center Study in Parallel Groups To Assess the Efficacy and Safety of Lys006 in Patients With Moderate To Severe Inflammatory Acne · 2019Their institution$54,969
Journey Medical Corporation · Dfd-29-Cd-004 · 2023Their institution$54,825
Bausch Health US, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study To Compare the Safety and Efficacy of Idp-126 Gel To Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris · 2022Their institution$54,158
Allergan Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy in Subjects With Glabellar Frown Lines · 2019Their institution$52,995
Kiniksa Pharmaceuticals, Ltd. · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2022Their institution$52,709
VYNE Pharmaceuticals Inc. · Serlopitant · 2020Their institution$50,396
Janssen Research & Development, LLC · Cnto1959pso3018 · 2023Their institution$50,012
AbbVie, Inc. · Skyrizi · 2019Their institution$45,812
SANOFI US SERVICES INC. · Efficacy, Safety, Pk, Biologics Monotherapy Study in Pts. With Moderate To Severe Ad · 2024Their institution$45,803
Kiniksa Pharmaceuticals, Ltd. · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2023Their institution$45,210
Eli Lilly and Company · A Randomized, Double-Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate To Severe Atopic Dermatitis · 2021Their institution$44,978
Eli Lilly and Company · A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis · 2021Their institution$44,812
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2019Their institution$43,053
SUN PHARMACEUTICAL INDUSTRIES INC. · A Study To Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate To Severe Genital Psoriasis · 2025Their institution$41,451
Bausch Health US, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study To Compare the Safety and Efficacy of Idp-126 Gel To Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris · 2021Their institution$41,110
LEO Pharma AS · Tralokinumab Trial in Adjunct Setting · 2019Their institution$39,011
Janssen Research & Development, LLC · Cnto1959pso3018 · 2024Their institution$38,519
E.R. Squibb & Sons, L.L.C. · Phase 2b Poc Pso Study - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study To Evaluate the Clinical Efficacy and Safety of Bms-986322 in Participants With Moderate-To-Severe Psoriasis · 2023Their institution$36,083
E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With An Induction Period Followed By A Randomized Maintenance Period To Evaluate the Clinical Efficacy and Safety of Bms-986165 in Subjects With Mod · 2020Their institution$33,947
Bausch Health US, LLC · Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study To Evaluate the Efficacy and Safety of Idp-124 Lotion for the Treatment of Moderate To Severe Atopic Dermatitis in Pediatric and Adult Subjects · 2019Their institution$33,819
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2021Their institution$33,224
Kiniksa Pharmaceuticals International, plc · A Phase 2a/B, Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Kpl-716 in Reducing Pruritis in Subjects With Prurigo Nodularis · 2024Their institution$32,673
Bausch Health US, LLC · A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of Idp-126 Gel in the Treatment of Acne Vulgaris · 2020Their institution$30,777
Taro Pharmaceuticals USA, Inc. · A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate the Efficacy and Safety of As012 in Subjects With Non-Segmental Vitiligo · 2021Their institution$28,580
Incyte Corporation · An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo · 2023Their institution$27,948
SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo--Controlled, Parallel Group, 3-Arm, Multinational, Multicenter, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Amlitelimab Monotherapy By Subcutaneous Injection in Adult Participants With Severe Alopecia Areata · 2025Their institution$27,537
Incyte Corporation · An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo · 2024Their institution$26,825
Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2022Their institution$24,821
Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2021Their institution$24,556
Teva Pharmaceuticals USA, Inc. · Study Comparing Tapinarof Cream 1% To Vtama (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis · 2025Their institution$24,290
Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis · 2021Their institution$23,577
Bausch Health US, LLC · A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of Idp-126 Gel in the Treatment of Acne Vulgaris · 2021Their institution$22,465
Eli Lilly and Company · A Multicenter, Open-Label, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2019Their institution$22,405
SANOFI US SERVICES INC. · A Long-Term Extension Study To Evaluate the Long-Term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate To Severe Atopic Dermatitis Who Participated in Ky1005-Ct05 (Dri17366) · 2025Their institution$22,257
Eli Lilly and Company · A Randomized, Double-Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate To Severe Atopic Dermatitis · 2020Their institution$22,163
Galderma Research & Development, LLC · Evaluation of Acne-Induced Hyperpigmentation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 G/G Cream Versus Vehicle Cream Over 24 Weeks · 2023Their institution$21,311
Bausch Health US, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Vehiclecontrolled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of Idp-126 Gel in the Treatment of Acne Vulgaris · 2019This clinician$21,215
SUN PHARMACEUTICAL INDUSTRIES INC. · Rxlc 2118 · 2024Their institution$20,757
SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof-of-Concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate To Severe Hidradenitis Suppurativa · 2024Their institution$20,300
SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo--Controlled, Parallel Group, 3-Arm, Multinational, Multicenter, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Amlitelimab Monotherapy By Subcutaneous Injection in Adult Participants With Severe Alopecia Areata · 2024Their institution$19,585
Allergan, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy in Subjects With Glabellar Frown Lines · 2021Their institution$19,491
Incyte Corporation · True Ad2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis · 2021Their institution$18,818
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2022Their institution$18,718
SUN PHARMACEUTICAL INDUSTRIES INC. · Efficacy and Safety of Ilumya in the Treatment of Scalp Psoriasis · 2021Their institution$18,279
SANOFI US SERVICES INC. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 3-Arm, Multinational, Multicenter Study To Evaluate the Efficacy and Safety of Amlitelimab By Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-To-Severe Atopic Dermatitis (Ad) Who Are on Background Topical Corticosteroids and Have Had An Inadequate Response To Prior Biologic Therapy Or Oral Janus Kinase (Jak) Inhibitor Treatment · 2025Their institution$17,800
Taro Pharmaceuticals USA, Inc. · A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate the Efficacy and Safety of As012 in Subjects With Non-Segmental Vitiligo · 2022Their institution$17,395
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2021Their institution$17,363
LEO Pharma AS · Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend · 2019Their institution$17,362
Eli Lilly and Company · A Randomized, Double-Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate To Severe Atopic Dermatitis · 2022Their institution$17,340
Arcutis Biotherapeutics, Inc. · A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Arq-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis Who Have Completed Preceding Studies Arq-151-301 Or Arq-151-302 · 2023Their institution$17,132
Janssen Research & Development, LLC · Study of Guselkumab in Skin of Color Participants With Moderate-To-Severe Plaque and/?Or Scalp Psoriasis (Visible) · 2025Their institution$16,804
Taro Pharmaceuticals USA, Inc. · Rxlc 2118 · 2023Their institution$16,786
Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2021Their institution$16,374
AbbVie, Inc. · 2019Their institution$16,062
Janssen Research & Development, LLC · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Jnj-77242113 for the Treatment of Participants With Moderate To Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment · 2025Their institution$15,933
Regeneron Pharmaceuticals, Inc. · An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-To-Severe Atopic Dermatitis · 2024Their institution$15,532
Novartis Pharmaceuticals Corporation · A Randomized Subject and Investigator Blinded Placebo Controlled Multi Center Study in Parallel Groups To Assess the Efficacy and Safety of Lys006 in Patients With Moderate To Severe Inflammatory Acne · 2021Their institution$15,410
Acrotech Biopharma Inc. · 2024Their institution$15,190
VYNE Pharmaceuticals Inc. · 2020Their institution$14,971
Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2025Their institution$14,549
Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-Controlled, Phase 2a Study To Assess the Efficacy, Safety and Tolerability of Gia632 in Adult Participants With Moderate To Severe Atopic Dermatitis · 2025Their institution$14,251
SUN PHARMACEUTICAL INDUSTRIES INC. · Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis · 2022Their institution$14,019
Eli Lilly and Company · A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis · 2021Their institution$13,948
SANOFI US SERVICES INC. · Registry To Characterize the Patients Who Receive Dupixent for Pn in A Real-World Setting · 2024Their institution$13,778
Bausch Health US, LLC · A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of Idp-120 Gel and Idp-120 Vehicle Gel in the Treatment of Acne Vulgaris · 2020Their institution$13,742
Bausch Health US, LLC · A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Study To Evaluate the Efficacy and Safety of Idp-124 Lotion for the Treatment of Moderate To Severe Atopic Dermatitis in Pediatric and Adult Subjects · 2020Their institution$12,965
E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment To Evaluate the Efficacy and Safety of Bms-986165 in Subjects With Moderate-To-Severe Plaque Psoriasis · 2023Their institution$12,848
Novartis Pharmaceuticals Corporation · A US Phase 3b, Multi-Center, Randomized, Double-Blind, Double-Dummy Study To Evaluate Efficacy of Remibrutinib Compared To Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled By Second Generation H1-Antihista · 2025Their institution$12,772
DERMIRA, INC. · A Randomized, Double-Blind, Placebo Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate To Severe Atopic Dermatitis · 2020Their institution$12,764
Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis · 2020Their institution$12,237
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2019Their institution$12,167
Eli Lilly and Company · A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis · 2021Their institution$12,104
E.R. Squibb & Sons, L.L.C. · A Phase 3b/4 Multi-Center, Randomized, Open-Label, Long-Term Safety Study of Deucravacitinib in Comparison To Ustekinumab in Participants With Moderate-To-Severe Plaque Psoriasis (Pragmatyk) · 2025Their institution$12,000
SANOFI US SERVICES INC. · A Phase 2, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Efficacy and Safety of Sar441566 in Adults With Moderate To Severe Plaque Psoriasis · 2024Their institution$12,000
Eli Lilly and Company · An Open-Label, 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2025Their institution$11,991
E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With An Induction Period Followed By A Randomized Maintenance Period To Evaluate the Clinical Efficacy and Safety of Bms-986165 in Subjects With Moderate To Severe Psoriasis · 2019Their institution$11,978
Eli Lilly and Company · A Phase 2b, Double-Blind, Placebo-Controlled Study To Evaluate Eltrekibart in Adult Participants With Moderate To Severe Hidradenitis Suppurativa · 2024Their institution$11,800
Vanda Pharmaceuticals Inc. · Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis · 2019Their institution$11,691
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 3, Multicenter, Open-Label Study To Evaluate the Long-Term Safety, Tolerability, and Efficacy of Tak-279 in Subjects With Moderate-To-Severe Plaque Psoriasis · 2024Their institution$11,555
SUN PHARMACEUTICAL INDUSTRIES INC. · Study To Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata · 2025Their institution$11,315
Eli Lilly and Company · Observation Priority E Short - Lebrikizumab - Atopic Dermatitis · 2025Their institution$11,102
SANOFI US SERVICES INC. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (Lsc) in Adults · 2025Their institution$10,800
Journey Medical Corporation · Dfd-29-Cd-004 · 2022Their institution$10,600
Incyte Corporation · A Study To Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis · 2024Their institution$10,494
Acrotech Biopharma Inc. · Medi-Mm36-302 · 2024Their institution$10,309
PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo · 2023Their institution$10,107
PFIZER INC. · A Phase 3 Randomized Doubleblind Vehiclecontrolled Study To Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment 2 Once Daily Over 52 Weeks in Pediatric and Adult Participants Ages 3 Months and Older With Mildtomoderate Atopic Dermatitis Who Responded To Twice Daily Crisaborole Ointment 2 Treatment · 2021Their institution$10,091
Amgen Inc. · Ph2 Dax Discoid Lupus Dle Ole · 2024Their institution$9,888
Regeneron Pharmaceuticals, Inc. · An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-To-Severe Atopic Dermatitis · 2025Their institution$9,357
E.R. Squibb & Sons, L.L.C. · Phase II Umbrella Ad - A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, 5 Parallel-Group Study of Bms-986166 Or Branebrutinib for the Treatment of Patients With Moderate To Severe Atopic Dermatitis · 2023Their institution$9,271
Boehringer Ingelheim Pharmaceuticals, Inc. · Flare Prevention Phase III Trial in Gpp · 2020Their institution$9,218
SANOFI US SERVICES INC. · Registry To Characterize the Patients Who Receive Dupixent for Pn in A Real-World Setting · 2025Their institution$9,073
Eli Lilly and Company · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study of Ly4100511 (Dc-853) for the Treatment of Adult Participants With Moderate-To Severe Plaque Psoriasis · 2024Their institution$9,000
Dermavant Sciences, Inc. · A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate To Severe Atopic Dermatitis in Children With Adults · 2023Their institution$8,836
AbbVie Inc. · Skyrizi · 2020Their institution$8,805
SANOFI US SERVICES INC. · A Phase Iib, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Dose Ranging Study of A Subcutaneous Anti-Ox40l Monoclonal Antibody (Ky1005) in Moderate To Severe Atopic Dermatitis · 2022Their institution$8,777
Dr.Reddy's Laboratories,Inc. · Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 Week Study To Assess the Efficacy and Safety of Ppc-06, Extended Release Tablets in Moderate To Severe Plaque Psoriasis · 2019Their institution$8,206
Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2023Their institution$8,039
Takeda Pharmaceuticals U.S.A., Inc. · A Study About How Well Tak-279 Works and Its Safety in Participants With Moderate-To-Severe Plaque Psoriasis During 52 Weeks of Treatment · 2023Their institution$8,000
E.R. Squibb & Sons, L.L.C. · Phase 2b Poc Pso Study - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study To Evaluate the Clinical Efficacy and Safety of Bms-986322 in Participants With Moderate-To-Severe Psoriasis · 2024Their institution$7,720
Regeneron Pharmaceuticals, Inc. · A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of Regn3500 Administered To Adult Patients With Moderate-To- Severe Atopic Dermatitis · 2019Their institution$7,681
E.R. Squibb & Sons, L.L.C. · A Study of Bms-986166 Or Branebrutinib for the Treatment of Participants With Atopic Dermatitis · 2024Their institution$7,589
Novartis Pharmaceuticals Corporation · A Randomized Subject and Investigator Blinded Placebo Controlled Multi Center Study in Parallel Groups To Assess the Efficacy and Safety of Lys006 in Patients With Moderate To Severe Inflammatory Acne · 2020Their institution$7,520
Boehringer Ingelheim Pharmaceuticals, Inc. · Flare Prevention Phase III Trial in Gpp · 2021Their institution$7,502
Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2020Their institution$7,465
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate To Severe Atopic Dermatitis · 2025Their institution$7,400
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2019This clinician$7,360
SANOFI US SERVICES INC. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof-of-Concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate To Severe Hidradenitis Suppurativa · 2025Their institution$6,900
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 True-V2 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2019Their institution$6,868
Janssen Research & Development, LLC · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Deucravacitinib Active Comparator-Controlled Study To Evaluate the Efficacy and Safety of Jnj-77242113 for the Treatment of Participants With Moderate To Severe Plaque Psoriasis · 2024Their institution$6,500
Eli Lilly and Company · A Phase 3 16-Week Randomized Double-Blind Placebo-Controlled Parallel- Group Study To Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis · 2023Their institution$6,410
PFIZER INC. · A Randomized Doubleblind Placebocontrolled Study To Demonstrate the Efficacy and Longterm Safety of Pf04965842 With Topical Corticosteroids in Adult Patients With Moderatetosevere Atopic Dermatitis · 2019Their institution$6,237
Eli Lilly and Company · A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab To Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis · 2019This clinician$6,151
E.R. Squibb & Sons, L.L.C. · Phase II Umbrella Ad - A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, 5 Parallel-Group Study of Bms-986166 Or Branebrutinib for the Treatment of Patients With Moderate To Severe Atopic Dermatitis · 2022Their institution$6,095
PFIZER INC. · A Phase 2a Multicenter Randomized Doubleblind Placebocontrolled 16week Study Evaluating the Safety and Efficacy of Pf06650833 Pf06700841 and Pf06826647 in Adults With Moderate To Severe Hidradenitis Suppurativa · 2020Their institution$5,620
Incyte Corporation · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of Incb054707 in Participants With Hidradenitis Suppurativa · 2021Their institution$5,500
Eli Lilly and Company · A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2023Their institution$5,460
PFIZER INC. · Prevention of Atopic Dermatitis Flare With Treatment of Crisaborole · 2019Their institution$5,375
Taro Pharmaceuticals USA, Inc. · A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate the Efficacy and Safety of As012 in Subjects With Non-Segmental Vitiligo · 2023Their institution$5,375
Amgen Inc. · Interchangeability Study Abp 654 · 2022Their institution$5,344
Incyte Corporation · An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo · 2025Their institution$5,161
Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2020Their institution$5,150
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2020Their institution$5,050
Regeneron Pharmaceuticals, Inc. · A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of Regn3500 Administered To Adult Patients With Moderate-To- Severe Atopic Dermatitis · 2020Their institution$5,011
ABBVIE INC. · A Study To Assess Adverse Events of Intramuscular Agn-151586 Injection in Adult Participants With Glabellar Lines · 2022Their institution$5,000
PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 To 18 Years of Age With Moderatetosevere Atopic Dermatitis · 2020Their institution$5,000
LEO Pharma AS · Efficacy and Safety of Leo 43204 in Field Treatment of Actinic Keratosis on Face Or Chest Including 12-Month Follow-Up · 2019Their institution$4,719
UCB SA · A Phase 3, Randomized, Double-Blind, Placebocontrolled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate To Severe Hidradenitis Suppurativa · 2020Their institution$4,558
Eli Lilly and Company · A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab To Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis · 2020Their institution$4,426
ABBVIE INC. · A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared To Secukinumab for the Treatment of Adult Subjects With Moderate To Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy · 2021Their institution$4,150
Regeneron Pharmaceuticals, Inc. · A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of Regn3500 Administered To Adult Patients With Moderate-To- Severe Atopic Dermatitis · 2021Their institution$4,064
Janssen Research & Development, LLC · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Jnj-77242113 for the Treatment of Participants With Moderate To Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment · 2023Their institution$4,000
PFIZER INC. · An Openlabel Extension Study To Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis · 2019Their institution$3,897
Amgen Inc. · Interchangeability Study Abp 654 · 2024Their institution$3,690
Eli Lilly and Company · An Open-Label, 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2024Their institution$3,604
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2022Their institution$3,360
Vanda Pharmaceuticals Inc. · Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis · 2020Their institution$3,330
Amgen Inc. · P2 Moderate-Severe Pdle · 2025Their institution$3,275
Janssen Research & Development, LLC · Noprodnap0029 · 2023Their institution$3,273
Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2023Their institution$3,229
Janssen Research & Development, LLC · A Phase 2a2b Multi Center Randomized Placebo and Active Comparator Controlled Double Blind Dose Ranging Study To Evaluate the Safety and Efficacy of Bermekimab Jnj77474462 for the Treatment of Subjects With Moderate To Severe Hidradenitis Suppurativa. · 2023Their institution$3,224
Dermavant Sciences, Inc. · An Open Label, Long-Term Extension Study To Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis · 2024Their institution$3,094
LEO Pharma AS · Tralokinumab: Trial in Adjunct Setting · 2020Their institution$3,040
Dr.Reddy's Laboratories,Inc. · Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 Week Study To Assess the Efficacy and Safety of Ppc-06, Extended Release Tablets in Moderate To Severe Plaque Psoriasis · 2020Their institution$3,000
LEO Pharma AS · Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend · 2020Their institution$2,829
PFIZER INC. · A Phase 3 Randomized Doubleblind Vehiclecontrolled Study To Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment 2 Once Daily Over 52 Weeks in Pediatric and Adult Participants Ages 3 Months and Older With Mildtomoderate Atopic Dermatitis Who Responded To Twice Daily Crisaborole Ointment 2 Treatment · 2022Their institution$2,743
PFIZER INC. · Prevention of Atopic Dermatitis Flare With Treatment of Crisaborole · 2020Their institution$2,742
SANOFI US SERVICES INC. · A Phase Iib, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Dose Ranging Study of A Subcutaneous Anti-Ox40l Monoclonal Antibody (Ky1005) in Moderate To Severe Atopic Dermatitis · 2024Their institution$2,693
LEO Pharma AS · Long Term Study Leo 90100 on the Body · 2019Their institution$2,637
Eli Lilly and Company · An Open-Label Study To Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab · 2023Their institution$2,502
Eli Lilly and Company · A Multicenter, Open-Label, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2020Their institution$2,500
Dermavant Sciences, Inc. · An Open Label, Long-Term Extension Study To Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis · 2023Their institution$2,500
PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo · 2022Their institution$2,495
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2020This clinician$2,341
Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2019Their institution$2,284
AbbVie, Inc. · Humira · 2019Their institution$2,150
AbbVie Inc. · Humira · 2020Their institution$2,150
Incyte Corporation · A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of Incb054707 in Participants With Hidradenitis Suppurativa · 2024Their institution$2,130
E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment To Evaluate the Efficacy and Safety of Bms-986165 in Subjects With Moderate-To-Severe Plaque Psoriasis · 2022Their institution$2,062
Eli Lilly and Company · A Phase 1 Double-Blind Randomized Placebo-Controlled Multiple-Dose Study To Evaluate the Safety Tolerability and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis · 2023Their institution$1,884
ABBVIE INC. · Chronic Plaque Psoriasis (Ps) Registry · 2022Their institution$1,790
ABBVIE INC. · A 10-Year, Post-Marketing, Observational Study To Assess Long Term Safety of Humira (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps) · 2021Their institution$1,720
Amgen Inc. · P2 Moderate-Severe Pdle · 2024Their institution$1,622
Eli Lilly and Company · A Multicenter, Open-Label, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate To Severe Atopic Dermatitis · 2019This clinician$1,252
E.R. Squibb & Sons, L.L.C. · A Study To Evaluate Effectiveness and Safety of Bms-986322 in Participants With Moderate-To-Severe Psoriasis · 2024Their institution$1,160
Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2022Their institution$1,127
E.R. Squibb & Sons, L.L.C. · A Study To Evaluate Effectiveness and Safety of Bms-986322 in Participants With Moderate-To-Severe Psoriasis · 2023Their institution$1,110
ABBVIE INC. · A Multicenter, Open Label Study To Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate To Severe Plaque Type Psoriasis (Limmitless) · 2023Their institution$1,050
Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis · 2022Their institution$1,004
E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment To Evaluate the Efficacy and Safety of Bms-986165 in Subjects With Moderate-To-Severe Plaque Psoriasis · 2021Their institution$1,000
Bausch Health US, LLC · A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of Idp-123 Lotion and Idp-123 Vehicle Lotion in the Treatment of Acne Vulgaris · 2019Their institution$975
Eli Lilly and Company · An Open-Label, Study To Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab · 2024Their institution$840
Eli Lilly and Company · An Open-Label 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2023This clinician$790
Amgen Inc. · P3 Ad Monotherapy Induction · 2023Their institution$787
Eli Lilly and Company · A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis · 2022Their institution$776
Janssen Research & Development, LLC · A Phase 2a2b Multi Center Randomized Placebo and Active Comparator Controlled Double Blind Dose Ranging Study To Evaluate the Safety and Efficacy of Bermekimab Jnj77474462 for the Treatment of Subjects With Moderate To Severe Hidradenitis Suppurativa. · 2024Their institution$735
Amgen Inc. · Astro P3 Ad Adolescent Mono · 2024Their institution$661
Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2024Their institution$552
Incyte Corporation · A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo · 2023Their institution$548
Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Blind Placebo Controlled 52 Week Study To Demonstrate the Efficacy Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 Ml Prefilled Syringes 300 Mg in Adult Subjects With Moderate To Severe Plaque Psoriasi · 2019Their institution$500
Incyte Corporation · A Study To Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis · 2025Their institution$371
PFIZER INC. · A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 To 18 Years of Age With Moderatetosevere Atopic Dermatitis · 2019Their institution$224
Eli Lilly and Company · A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis · 2020Their institution$150
Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2021This clinician$90
SUN PHARMACEUTICAL INDUSTRIES INC. · Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis · 2023Their institution$75
Eli Lilly and Company · A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab To Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis · 2020This clinician$33
Eli Lilly Export S.A. Puerto Rico Branch · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate To Severe Atopic Dermatitis · 2019Their institution$14
Eli Lilly and Company · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata · 2019This clinician$5

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
100.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1326018987
Licence
CA G53340California G53340: Current · expires 2028-04-30
Trained
University of Southern California Keck School of Medicine, 1993
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
2557 Mowry Ave, Ste 34, Fremont, CA, 94538
NPI first listed
2006-01-25
NPI last updated
2010-10-01

This is when the NPI record was last certified, not a medical board exam.